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ABSTRACT 
THEORETICAL AND EXPERIMENTAL STUDIES ON 
MANIPULATION OF FLUORESCENCE BY GOLD NANOPARTICLE: 
APPLICA TION FOR MOLECULAR IMAGING 
Jianting Wang 
December 2011 
Gold nanopartic1es (GNPs) have shown beneficial properties for biomedical use, 
e.g., their non-toxic nature and surface properties for easy modification. Upon receiving 
light, they generate a strong surface plasmon field, which can alter the fluorescence of 
fluorophores. The level and type of the fluorescence alteration depend on the GNP size 
and shape, excitation (Ex)/emission (Em) wavelengths and quantum yield of the 
fluorophore, as well as the distance between the fluorophore and GNP. 
In this dissertation, the effect of the properties listed above on the fluorescence 
output was theoretically analyzed for the fluorophores frequently used in biomedical 
studies. For fluorescence quenching, fluorophores with the Em wavelength near the GNP 
plasmon resonance peak (520 nm) are better suited. As the Em wavelength increases, a 
shorter distance is required for achieving the same level of quenching. A bigger GNP 
requires shorter distance for quenching. To obtain fluorescence enhancement, the Em 
wavelength of the fluorophore needs to be longer than the GNP plasmon resonance peak 
(e.g., > 650 nm). The fluorophore with lower intrinsic quantum yield tends to be 
VI 
enhanced more. The GNP needs to be sufficiently large (> 5 nm), and a bigger GNP 
provides a higher maximum enhancement. 
Utilizing the quenching/enhancement ability of GNPs, a near-infrared (NIR) 
contrast agent that emits fluorescence at a higher level only at the particular cancer site 
was developed. Cypate, a safe NIR fluorophore, was selected as the fluorophore because 
NIR penetrates deeper into tissue and because Cypate is non-toxic. Cypate was 
conjugated to a GNP via two spacers. One is short for the quenching and with a substrate 
for a breast cancer-specific enzyme, urokinase-type plasminogen activator (uPA). The 
other is a long, biocompatible polymer chain for fluorescence enhancement. The 
fluorescence of the contrast agent was quenched by GNP by 93%. In the presence of uP A, 
the short spacer was cleaved and the remaining long spacer enhanced fluorescence 1.8 
times. 
The study results are beneficial for developing efficacious optical contrast agents. 
This novel contrast agent can detect and diagnose breast cancer with high specificity and 
sensitivity, as FRET or molecular beacon but with a higher sensitivity and without the 
restriction of using DNAIRNA segments. 
vii 
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Fluorophores have been extensively used as a signal mediator in the biomedical 
research and disease diagnosis/prognosis. Artificial manipulation of the fluorescence of a 
fluorophore can be highly beneficial for improving the specificity andlor sensitivity of 
biosensing/bioimaging. For example, fluorescence quenching can be used for negative 
sensing or for conditional de-quenching to increase specificity. Fluorescence enhancing 
can improve sensitivity and the signal to noise ratio. 
Since fluorescence is generated by the electrons that are excited by photonic 
energy, a localized entity affecting the electron state of the fluorophore can change the 
fluorescence output. Nano-sized metal particles forming a strong electromagnetic 
(plasmon) field upon receiving photonic energy can be, therefore, good candidates for 
this purpose [Lakowicz, 2005; Zayats, et al., 2005; Evanoff and Chumanov, 2005]. Gold 
nanoparticles (GNPs) are one of the most attractive metal nanoparticles for biomedical 
applications for this purpose because they are chemically stable and non-toxic and also 
because the gold-thiol chemistry for surface conjugation of biomolecules is well 
established [Connor, et al., 2005; Love, et al., 2005; Shukla, et al., 2005], 
Fluorescence quenching and enhancement using GNPs have been explored by 
many researchers. The type and the level of fluorescence alteration by GNPs depend on 
parameters including the metal type, particle size; the excitation and emission 
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wavelengths and the quantum yield of the fluorophores; and the distance between the 
fluorophore and the particle. In this dissertation, the effect of these parameters on the 
plasmon field distribution of GNPs and on the fluorescence alteration was analyzed for 
commonly used fluorophores in biomedical studies. The study result is expected to 
provide information for selecting fluorophore, GNP size, distance between the 
fluorophore and the GNP, in designing the efficacious contrast agents for molecular 
Imagmg. 
In parallel to the theoretical analyses, a safe, near-infrared (NIR) contrast agent 
for cancer detection was developed. The contrast agent specifically targets the cancer 
cell, and it emits fluorescence, only in the presence of the enzyme secreted by a particular 
breast cancer type, at a highly enhanced level. Thus, it provides high specificity and 
sensitivity for cancer detection. It can also be used to characterize the cancer type 
(diagnosis) by its ability of recognizing the particular enzyme. The same approach can 
also be used for other disease diagnoses. This contrast agent can be potentially combined 
with cancer treatment function (e.g., photo-dynamic therapy, hyperthermia) to enable 
seamless diagnosis and treatment. 
The structure of this dissertation after this introduction is as follows: 
Chapter II presents the BACKGROUND information on the fluorophore, metal 
(especially gold) nanoparticles, fluorescence quenching and enhancement by GNPs, and 
the mechanism and mathematic models of fluorescence alteration by GNPs. 
Chapter III describes the MATERIALS, INSTRUMENTS, AND METHODS 
used in theoretical and experimental studies. 
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Chapter IV contains the RESULTS AND DISCUSSIONS of the theoretical 
analyses of the factors affecting fluorescence alteration by GNP, and the experimental 
study of fluorescence quenching, restoration, and fluorescence enhancement of Cypate by 
GNPs. 
Chapter V concludes (CONCLUSIONS) the studies performed. 
In Chapter VI, suggested FUTURE WORKs are presented. 
In the APPENDIX, the application of gold nanoparticle reagent in our fiber-optic 






Fluorophores are molecules that absorb light at a particular wavelength and emit 
light at another but equally specific wavelength [Hercules, 1966]. The process is such 
that the electrons of the fluorophore absorb photons and the photons raise the energy 
level of the electrons to an excited state. During the excitation period, some of the energy 
is dissipated by molecular collisions or transferred to a proximal molecule, and then the 
remaining energy is emitted as photons to relax the electrons back to their ground state. 
Because the emitted photons usually carry energy less than the one received, they are 
emitted at a longer wavelength. The wavelength shift between the excitation and 
emission lights is called the Stokes Shift and each fluorophore has its distinct 
characteristic Stokes shift. If the Stokes Shift is very small and the excitation and 
emission wavelengths greatly overlap, the detection of emitted fluorescence can be 
difficult to distinguish from the excitation light. Conversely, fluorophores with large 
Stokes shifts are easier to use because the two can be distinguished better [Lakowicz, 
2006]. Since the emitted light (fluorescence) can be distinguished from the excitation 
light and is at a particular wavelength, one can use it as an optical signal [Hercules, 1966; 
Rendell, 1987; Guilbault, 1990]. Fluorophores have been, therefore, extensively used in 
4 
biosensing and imaging for detecting biomolecules, monitoring/studying biological 
processes, diagnosing/prognosing diseases, etc. [Choy, et ai., 2003]. 
Early studies using fluorophores employed those emitting the light mainly in the 
visible range of the electromagnetic spectra (e.g., 400-700nm) because of the limitation 
in detection. The advancement in technology has allowed the fluorescence detection 
beyond the visible spectra and into the ultraviolet (UV, e.g., 10-400 nm) and near infrared 
(NIR) ranges (e.g., 700-900 nm). The new fluorophores and detectors offer greater 
variability, versatility, and multiplexing capabilities. 
The quantum yield (QY) of a fluorophore is the ratio of the number of photons 
emitted as fluorescence to that of the photons absorbed, i.e., the emission efficiency of 
the fluorophore [Lakowicz, 2006]. QY is unique for each fluorophore. In sensing or 
imaging applications, fluorophores with higher QY is desired because they provide 
greater sensitivity. 
Photostability is another important property of a fluorophore. When a fluorophore 
IS exposed to an excitation light, the fluorescence level decreases over time due to 
photon-induced chemical damage, and the decrease in the fluorescence is called 
photobleaching [Lakowicz, 2006]. Photostability is very important for optical imaging, 
especially in optical microscopy where the excitation light intensity is high. 
Other important properties of fluorophores may include functional groups for 
bioconjugation, water-solubility, toxicity, pH-sensitivity, etc. Depending on the 
application, the fluorophore with desired properties needs to be carefully selected. 
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1. Small Fluorescent Organic Molecules 
Small fluorescent organic-molecules are often called organic dyes. Organic dyes 
are small molecules, at the scale of ~0.5 nm [Resch-Genger, et ai., 2008]. The small size 
of these fluorophores is an advantage for bioapplications because they can be conjugated 
to macromolecules, such as antibodies, biotin or avidin, without interfering with their 
biological function. The first fluorescent compound used in biological research was 
Fluorescein synthesized by Adolf von Baeyer in 1871 [Guilbault, 1990; Resch-Genger, et 
ai., 2008; Zhang, et ai., 2002; Waggoner, 2006]. Fluorescein is still widely used today 
and its derivatives have been produced to improve their photostability and solubility. 
Currently a wide variety of dyes are available with various excitation/emission spectra, 
optimal quantum yields, excitation coefficients and functional groups for conjugation are 
available. Examples include rhodamine (TRITC), coumarin, cyanine, Alex Fluors, and 
their derivatives [Rietdorf, 2005]. 
NIR fluorophores have attracted much attention especially in optical imaging of 
human because they offer several advantages over the fluorophores in the visible range. 
NIR is absorbed less by biological tissues than the visible light. In tissue, there is less 
autofluorescence in NIR than in the visible range, thereby less background noises 
[Kobayashi, et ai., 2002]. In the infrared region, photons are absorbed by water much 
more than in NIR. NIR, therefore, provides a window of opportunity with deeper tissue 
penetration, i.e., 2-4 centimeters [Marshall, et ai., 2010]. Compared to other commonly 
used imaging techniques, such as magnetic resonance imaging (MRI), computed 
tomography (CT), and photon emission tomography (PET), optical imaging is more 
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sensitive, more cost-effective, rapid, and easy to use [Choy, et aI., 2003; Cassidy and 
Radda, 2005; Mankoff, 2008, Marshall, et ai., 2010]. 
The early NIR imaging usually used angiogenesis-mediated absorption contrast. 
The absorption of NIR light in a typical tissue having 8% blood volume and 29% lipid 
content, the dominant absorber is hemoglobin, accounting for 39-64% of total absorbance 
at NIR wavelength [Lim, et ai., 2003]. NIR optical tomography using time-dependent 
measurements of light propagation in the breast has been developed for breast cancer 
screening for two decades [Kang, et aI., 1993; Ntziachriostos and Chance, 2001; Honar 
and Kang, 2002; Wang, et ai., 2010]. There has been remarkable advance in the 
application of NIR on detecting the angiogenesis and increased hemoglobin absorbance 
for contrast. However, the angiogenesis-mediated absorption contrast only for optical 
mammography reduces the potential for using NIR techniques to assess sentinel lymph 
node staging, metastatic spread, and multifocality of breast disease [Frangioni, 2003; 
Hawrysz and Sevick-Muraca, 2000]. Recent research has been focused on the use of 
contrast agents for the molecular-based, diagnostic imaging [Marshall, et aI., 2010]. 
Exogenous, optical contrast agents for human use have been limited to the safe 
organic dyes. In 1959, Indocyanine green (lCG) was approved by the United States Food 
and Drug Administration (FDA) as a contrast agent for retinal angiography for both 
absorption and fluorescence imaging. Currently, it still remains the only FDA-approved 
NIR fluorophore [Alford, et ai., 2009; Marshall, et ai., 2010]. Fluorescent imaging with 
ICG has been used for the vascular mapping and tissue perfusion measurement 
[Frangioni, 2003]. ICG angiography is a routine test in the ophthalmology clinic for 
detecting the posterior uveitis [Herbort, et aI., 1998] and central serous chorioretinophthy 
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[Chen, et ai., 1999]. ICG has been also used to image the vasculature [Raabe, et ai., 
2003] and cerebrospinal fluid in brains [Sakatani, et ai., 1997] of both rats and human, 
for improved tumor localization and the assessment of post-resection margins with high 
sensitivity and specificity [Haglund, et ai., 1994]. It has also been studied for sentinel 
lymph node mapping for cancer staging in breast, skin and gastric cancers [Marshall, 
2010]. 
2. Quantum dots 
Quantum dots (QDs) are semiconductor nanocrystals and fluorescent 
nanoparticles (2-10 nm) that contain a core of the group II and VI elements or group III 
and V elements [Gao, 2005; Medintz, 2005]. CuCI nanocrystals in colloidal solutions are 
first discovered in the 1980s by Alexei Ekimov [1981] and by Rossetti [1983], and the 
term "quantum dot" was first used by Mark Reed [1988]. In 1993, Murrays, et ai. [1993] 
developed the procedure for synthesizing of high-quality CdSe QDs dispersed in organic 
solvents. 
In QDs, the excitons are confined in all three spatial dimensions due to the small 
size of the particle. Therefore, the electronic characteristics of these particles are closely 
related to the size and shape of the individual crystal. Generally, smaller QD results in 
larger band gap, which means the difference in energy between the highest valence band 
and the lowest conduction band is greater. Therefore, more energy is needed to excite the 
QD, and thus, more energy is released whe~ the crystal returns to its resting state. As a 
result, by changing the size and shape of the particle, the excitation and emission 
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wavelengths can be tuned, typically from the visible to NIR range [Reed, et aI., 1988; 
Wang, et aI., 2001; Michalet, et ai., 2001; Altinoglu and Adair, 2010]. 
Compared to organic dyes, QDs have higher quantum yield [>50%, West and 
Halas, 2003] and higher molar extinction coefficients, e.g., roughly an order of 
magnitude higher than even the strongly absorbing Rhodamine 6G [Leatherdale, et ai., 
2002; Smithpeter, et ai., 1998]. As a result, they emit brighter fluorescence (most QDs 
are approximately 10-20 times brighter) than organic dyes [Dabbousi, et ai., 1997; Chan 
and Nie, 1998]. Since the light absorption by QDs is greater at a shorter wavelength 
(higher energy), QDs exhibit an almost continuous, broad-band absorption and a narrow 
emission spectrum, resulting in a large effective Stokes shifts [Cai, et ai., 2007; Michalet, 
et ai., 2005]. Therefore, the excitation and emission spectra of QDs are well separated. 
QDs also exhibit photostability higher than organic dyes [Santra and Dutta, 2007]. 
QDs became fluorescent probes for the biosystem in 1998 when two groups 
simultaneously reported the procedures for making water-soluble QDs and conjugating 
them to biomolecules [Chan and Nie, 1998; Bruchez et aI., 1998, Mazumder, et ai., 
2009]. Since then, extensive research has been directed toward using QDs in biosensing 
and bioimaging. QD labeled microorganisms, biomarkers, cancer cells, etc. have been 
studied in detecting biomolecules and in disease diagnosis, but not in humans 
[Mazumder, et ai., 2009]. Even though NIR QDs have a great potential, there are only a 
few reports for in vivo NIR imaging using QDs [Altinoglu and Adair, 2010], and all of 
these reports employed QDs as a tracer in sentinel lymph node mapping. Although some 
researchers assert that the surface modification of QDs may eliminate the potential harm 
[Gerion, et aI., 2001; Altinoglu and Adair, 2010; Resch-Genger, et aI., 2008], the 
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cytotoxicity to organelles and membranes, induced apoptosis, and peroxidative stress, are 
still serious concerns in using QDs for human [Jaiswal and Simon, 2004; Hoshino, et aI., 
2004; Ballou, et aI., 2004; Ryman-Rasmussen, et al., 2007]. 
3. Fluorescent proteins 
Green fluorescent protein (GFP) was originally isolated from the light-emitting 
organ of the jellyfish Aequorea victoria by Shimomura, et aI., in 1962. Thirty years later, 
Chalfie, et al. [1994] characterized the DNA encoding of GFP and used it as a gene 
expression reporter. In 2006, Martin Chalfie, Osamu Shimomura, and Roger Y. Tsien 
shared a Nobel Prize in Chemistry for their discovery of GFP. Since then, derivatives of 
the GFP and many other fluorescing proteins were developed in biological expression 
systems, and they are now frequently used in biological research [Choy, et aI., 2003]. The 
benefit of using this type of fluorophores is that the plasmid expression can be introduced 
into cells, organs or organisms, to express the fluorophore either alone or fused to the 
protein of interest in the biological processes studied [Miyawaki, et aI., 2003]. However, 
the use of fluorescent proteins can be time consuming, and also expressing large amounts 
of light-producing proteins can cause reactive oxygen species, introducing artifactual 
responses or toxicity. In addition, the size of the fluorescent protein may change the 
biological function of the cellular protein to which the fluorophore is fused. Biological 
fluorophores do not typically provide the level of photostability and sensitivity offered by 
synthetic fluorescent dyes [Prasher, et aI., 1992; Kain, et aI., 1995; Choy, et al., 2003]. 
In terms of the usage of fluorophores for human, until now, only a few organic 
dyes are used for human due to the safety issue [Kovar, et al., 2007]. Although several 
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organic dyes are used for in vivo animal studies, for humans, only fluorescein and ICG 
were approved by the US FDA [Alford, et aI., 2009], and for NIR, ICG is the only one. 
Cypate, a derivative of ICG, is demonstrated to be non-toxic to animals up to 10 
Ilmol/kg, and considered to be a "biocompatible" dye [Achilefu, et aI., 2002], although it 
has not yet been submitted for FDA approval. 
4. Specially designed fluorescent probes 
The fluorescence emission level can be influenced by interactions with other 
fluorescing or non-fluorescing molecules. These interactions can be beneficially used to 
design probes highly specific to a particular biomolecule for biosensing or molecular 
imaging, in such a way that the fluorescence level or emission wavelength changes in the 
presence of the biomolecule. The most frequently used fluorescent probes include the 
molecular beacon and the fluorescence resonance energy transfer (FRET, also known as 
Forster resonance energy transfer). 
Molecular beacon was first developed by Tyagi and Kramer [1996]. In the 
molecular beacon. a fluorophore and a quencher are attached to the two ends of a hairpin-
shaped oligonucleotide. When a fluorophore is in contact with a quencher, the energy 
from excitation is transferred to the quencher, and this energy is then lost by heat 
[O'Reilly, 1975]. In the absence of a complimentary target sequence, the beacon remains 
closed and there is no appreciable fluorescence. Once the single stranded loop portion of 
the hairpin hydridizes to the target sequence. the resulting spatial separation of the 
t1uorophore from the quencher leads to fluorescence emission. Molecular beacons have 
become widely used in chemistry, biology, biotechnology and medical sciences for the 
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particular biomolecular recognition, due to the easy synthesis, molecular specificity and 
structural tolerance to various modifications [Tan, et al., 2004]. For example, molecular 
beacons have been commonly used for real-time monitoring of DNA or RNA 
amplification during polymerase chain reaction (PCR) [Li and Tan, 2003]. Since the 
initial development there have been various modifications of molecular-beacon sensors, 
including miniaturized surface-immobilized hybridization assays and micro arrays [Vet, et 
al., 2002; Broude, 2002; Lou and Tan, 2002, Epstein, et ai., 2003]. Molecular beacons 
have also been used in monitoring genes in living cells. 
FRET occurs between two fluorophores. Excitation energy is transferred from a 
donor to an acceptor fluorophore. In the donor-acceptor pair, the emission wavelength of 
the donor fluorophore must match the excitation wavelength of the acceptor molecule 
[Didenko, 200 1]. As a result, the donor molecule fluorescence is quenched, and the 
acceptor molecule becomes excited. It then loses energy via heat or the fluorescent 
emission [Didenko, 2001]. The initial theory of FRET was developed by Theodor Forster 
in 1948. The distance dependent FRET was experimentally confirmed by Stryer and 
Haugland [1967] and Haugland, et al. [1969]. For FRET to occur, the distance between 
the donor and the acceptor molecule must be within a distance of 0.5-10 nm, depending 
on the specific donor-acceptor pair. The first biological applications of this phenomenon 
started in the 1970s, dealing primarily with protein research [Didenko, 2001]. FRET-
based DNA applications began to appear in the mid-1980s and 1990s and has gained 
popularity because of the availability of the fluorescent protein [Piston, 2007; Miyawaki, 
et al., 1997; Patterson, et al., 2001; Chalfie, et al., 1994]. The detection of FRET and its 
disruption are both used in the assays. In FRET probes, the fluorophores are usually 
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labeled onto two oligonucleotides separately, and when these two oligonucleotides form a 
duplex, bringing the two fluorophores in close proximity, FRET occurs. Alternatively, 
the hairpin configuration of the oligonucleotide labeled with the donor and acceptor 
fluorophores can also result in FRET. DNA-based FRET probes are used in vitro and in 
vivo in many applications monitoring various types of DNA and RNA reactions, 
including peR, hybridization, ligation, cleavage, recombination, and synthesis. They are 
also applied in sequencing, mutation detection, and as parts of biosensors to assess the 
concentration of lead, DNNRNA and protein [Didenko, 2001; Piston, 2007]. 
B. METAL NANOPARTICLES AND FLUORESCENCE 
With the advance in nanotechnology, the fluorescence alteration by metal 
nanostructures has attracted much interest. These nanostructures are able to not only 
quench the fluorescence, but also enhance the fluorescence intensity, providing the 
sensing/imaging with the potential to increase the sensitivity and specificity. 
1. Surface plasmon field of metal nanoparticles 
Surface plasmon is coherent electron oscillation that exists at the metal-dielectric 
material interface, such as a thin metal film, a small metal particle, or a sharp metal tip. 
The existence of surface plasmon was first predicted in 1957 by Ritchie [1957]. The 
localized surface plasmon polariton is collective electron-charge-oscillation in metallic 
nanoentities, including nanoparticles, excited by light. The surface plasmon polariton can 
propagate along the metal surface until the energy is lost either by the absorption by the 
metal or by the radiation into the free-space. This propagating energy forms a surface 
plasmon field near the metal surface. For metal nanoparticles, the surface plasmon is 
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highly localized near the surface and rapidly decays from the particle surface into the 
dielectric environment [GonzaIez-Diaz, et al., 2008]. The local surface plasmon exhibits 
enhanced field strength at around the resonance wavelength and it is the highest at the 
resonance wavelength. The resonance condition is determined by the absorption 
spectroscopy and depends on the size and shape of the particle and dielectric properties of 
both the metal and the surrounding material. For noble metals, such as gold and silver, 
the resonance wavelength is in the visible light range [Evanoff and Chumanov, 2005; 
Kreibig and Vollmer, 1995]. Therefore, gold and silver nanoparticles have been studied 
extensively in their interaction with optical probes, such as fluorophores [Lakowicz, 
2005; Zayats, et aI., 2005]. 
For bio-application, gold nanoparticles (GNPs) have been studied the most 
because they have been well characterized, and they have little to no long-term toxicity or 
other adverse effect in vivo [Connor, et aI., 2005; Shukla, et al., 2005]. Colloidal gold has 
been safely used to treat rheumatoid arthritis for over 50 years [Merchant, 1998; Root, et 
aI., 1954]. Recent study results indicate that the colloidal GNPs coated with a protective 
layer of polyethylene glycol (PEG) exhibit excellent in vivo biodistribution and 
pharmacokinetic properties after systemic application [James, et aI., 2007; Paciotti, et aI., 
2004; Paciotti, et aI., 2006]. Currently, a PEG coated GNP with targeting molecule is 
already in a phase I clinical trial for advanced-staged cancer patients [Libutti. el (II., 
2010]. 
2. Fluorescence alteration by gold nanoparticies 
Since fluorescence is generated by the electrons excited by photonic energy, a 
localized entity affecting the electron state of the fluorophore can change the fluorescence 
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output. GNP forming surface plasmon upon receiving photonic energy can be, therefore, 
good candidates for this purpose [Lakowicz, 2005; Zayats, et ai., 2005]. When a 
fluorophore is placed very close to a GNP (e.g., within a few nanometers), the 
fluorescence is usually quenched because the fluorophore donates the excited electrons to 
the GNP, thus the electrons take the non-radiative pathway. However, as the distance 
increases the electric field (plasmon field) near the GNP is still strong but the GNP is not 
able to interact directly with the electrons of the fluorophore. Thus, the fluorescence can 
be enhanced [Eustis and EI-Sayed, 2006]. 
The fluorescence quenching using GNPs has been studied by many researchers: 
Ghosh, et ai. [2004] studied the effect of the GNP size on the fluorescence quenching; 
Schneider, et ai. [2006] showed the degree of quenching as a function of the distance 
between a GNP and a fluorophore; Dulkeith, et ai. [2002] observed a decrease in the 
radiative decay of a fluorophore placed near a GNP; Kato and Caruso [2005] utilized the 
quenching phenomenon in a competitive fluorescence immunoassay for biosensing and 
imaging; Dubertret, et ai., [2001] used GNPs as fluorescence quenchers in DNA 
molecular beacons; etc. 
Utilizing GNPs for enhancing the fluorescence of fluorophores has also been 
previously explored by several researchers. Nakamura et ai. [2005] studied the level of 
the fluorescence enhancement with respect to the GNP size, for the fluorophore Rose 
Bengal; Kuhn, et ai. [2006] and Anger, et ai. [2006] observed the change in the 
fluorescence of Nile Blue with the distance from a GNP; Laurent and Asahi [2009] 
obtained fluorescence enhancement of a film of N,N' -bis[2,5-di-tert-butylphenyl]-
3,4,9,1O-perylene dicarboximide by a single GNP. 
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C. THEORY OF FLUORESCENCE ALTERATION BY METAL PARTICLES 
Although numerous studies have demonstrated the ability of fluorescence 
alteration by GNPs, to beneficially utilize fluorescence manipulation in designing 
contrast agents, it is very important to thoroughly understand the correlation between the 
manipulable parameters of the system and the fluorescence output. Theoretical analysis 
using the mathematical model may be one of the most efficient ways for this purpose. 
1. Mechanisms and Parameters 
The mechanism of fluorescence alteration by metal nanoparticles has been studied 
by many physicists as early as in 1980s. Gersten and Nitzan [1981], and Nitzan and Brus 
[1981] studied the fluorescence from a single dye molecule adsorbed on a spherical metal 
particle. They pointed out that the fluorescence change is a result of the competition 
among the enhanced excitation, enhanced radiative and nonradiative decay rates near the 
metal particle surface. They concluded that, for the dyes with low quantum yield, the 
fluorescence is suppressed directly on the metal particle surface, but increased to a 
maximum at a well-defined distance from the surface. These early theoretical 
speculations were later verified by experiments with silver islands deposited on silicon 
oxides [Wokaun, et al., 1983; Lakowics, 2005]. Anger, et al. [2006] and Kuhn, et al. 
[2006] verified this theoretical prediction of fluorescence using a single-GNP and single-
dye system. This mechanism has been well accepted by many researchers [Wokaun, et 
al., 1983; Anger, et aI., 2006; Farahani, et al., 2005; Bharadwaj and Novotny, 2007], 
although these researchers may use different mathematical models for the fluorescence 
alteration by metal nanoparticles. 
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The main mechanism of fluorescence alteration and the parameters affecting the 
fluorescence can be described as follows [Gersten and Nitzan, 1981; Bharadwaj and 
Novotny, 2007]: When a fluorophore is placed in an electromagnetic field (plasmon 
field) generated by a metal nanoparticle exposed to the incident light at a particular 
wavelength, two main changes occur with the fluorescence output: (a) its excitation 
decay rate (Fig. la) increases; (b) its the quantum yield (Fig. Ib) changes by the increase 
in the radiative molecular decay rate, by the re-routing of the radiative decay to non-
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(a) GNP size (1) 
Excitation decay 
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Intrinsic quantum yield (4) 
Figure 1. Mechanisms (a and b) and the parameters (1-4) involved in the 
fluorescence alteration by GNPs 
The increase in the excitation decay rate is caused by the plasmon field generated 
by the GNP upon receiving the photonic energy. The level of the increase is determined 
by the plamson field strength, which depends on the GNP size and the wavelength of the 
incident light (in a practical sense, the excitation wavelength of the fluorophore) and the 
distance between the fluorophore and the GNP. The change in the quantum yield is 
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affected by three different factors. (1) The increase in the radiative decay rate of a 
fluorophore is caused by the plasmon field [Gersten and Nitzan, 1981; Bharadwaj and 
Novotny, 2007]. (2) The non-radiative decay rate is induced by the GNP and it strongly 
depends on the emission (Em) wavelength of the fluorophore. (3) The intrinsic quantum 
yield of the fluorophore in the medium of interest also affects the results, especially when 
the value is exceptionally small [Gersten and Nitzan, 1981; Nitzan and Brus, 1981; 
Wokaun, etal., 1983]. 
The four main system parameters affecting the fluorescence change by a GNP are, 
therefore, the GNP size, the Ex and Em wavelengths, and the intrinsic quantum yield of 
the fluorophore (Fig. 1). In addition to these four, an important, manipulable parameter is 
the distance between a fluorophore and a GNP, because the plasmon field strength decays 
with the distance from the GNP. To achieve a desired fluorescence alteration by GNPs, 
therefore, it is helpful to thoroughly understand how these five parameters affect the 
fluorescence output. 
2. Mathematical model for plasmon field strength near a GNP 
(a) Plasmon field 
The plasmon field strength around a metal nanoparticle has been frequently 
analyzed by the Mie theory [Born and Wolf, 1999; Hartling, et al., 2007]. The Mie theory 
is based on the scattering of electromagnetic radiation by spherical particles and it is an 
analytical solution of the Maxwell equation [Mie, 1908]. In biomedical applications, 
metal nanoparticles are usually coated with a polymer layer to stabilize the particle and 
increase the hydrophicility. Therefore, the effect of the layer on the field distribution 
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must be considered. Neeves and Birnboim [1989] extended the previous model for bare . 
metal nanoparticle to the one for the field strength near a core-shell nanoparticles 
dispersed in a dielectric medium. This particular model is limited to the dipolar 
contribution. The particle concentration is to be sufficiently dilute so that the inter-
particle interaction may be ignored, and the intrinsic dielectric non-linearity is neglected 
[Neeves and Bimboim, 1989]. The model uses spherical coordinate system (Fig. 2). The 
GNP (radius, rl) is placed in the center of the coordinate (Fig. 2a) and it is coated with a 
shell (thickness, r2-rl). The dielectric permittivities of the core, the shell and the medium 
are c/ , £ 2' and £ 3' respectively (Fig. 2b). An incident light (g) is applied in the z 





iii ....--- Incident Electric Field 
(a) (b) 
Point of interest 
Figure 2. (a) The coordinates used in the computation of the plasmon 
field strength on and around a GNP and (b) a schematic diagram of a 
GNP with polymer coating in a medium. 
The plasmon field strength (E) at a position r in the medium can be then described 
as in Eq (1). 
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(1) 




The factor P is the ratio of a shell volume to total particle volume. The field strength 
inside the shell (E1ayer; in our case, biopolymer coating) is: 
(5) 
For a GNP, £] is wavelength dependent. It is available as experimental data 
[Johnson and Christy, 1972], or it may be obtained by the Drude-Lorentz model (Eq. 6): 
( 
2 1 2 1 ) 
£) ( m) = Eo 1 - m p 2. + m p 2 2. , 
m +lmYj mo -m +lmYb (6) 
where i denotes imaginary number; W is the frequency of the incident light; W o, bound 
electron resonant frequency; wp, plasma frequency; and 
(7) 
7:j and 7:b are the free electron scattering and the bound electron decay time, respectively. 
Vjis the Fermi velocity and Lo, the free electron scattering time in the bulk material. The 
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dielectric function of a GNP by Drude-Lorentz model has been confirmed to agree with 
the experimental data by Neeves and Birnboim [1989]. 
(b) Fluorescence change of a fluorophore near a GNP 
The two approaches in developing the theoretical model for the fluorescence of a 
fluorophore affected by a metal nanoparticle are the steady state approach and the 
quantum mechanical approach. Gersten and Nitzan [1981] developed the models in both 
way and their models were often used by others. 
(b-i) Steady state model 
This model is for a system with a single fluorophore and a single metal 
nanoparticle. The relationship between an excited fluorophore and a metallic particle is 
presented with the dipolar and higher order multipolar contributions. For the particles 
with the size corresponding to the Rayleigh limit (dimensions s IJI0, A is the wavelength 
of the incident light or fluorescence), only the dipolar part is relevant for fluorescence 
radiation. Gersten and Nitzan pointed out that the fluorescence change (Y) of a 
fluorophore near a metal nanostructure is a product of two factors: L( w exc )' the 
amplification number of the local field, and Z( wf/u)' the partitioning of the excitation 
energy into the various radiative and non-radiative decay channels, by the presence of the 
particle. 
y = IL( W exc )12 Z( wf/u)' (8) 
where Wexc is the excitation frequency. L( W exc) can also be expressed as ElF: as used in 
equation (1). 
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Equation (8) was used later by many other researchers [Kummerlen, et ai., 1993; 
Nakamura, et ai., 2005; Kuhn, et ai., 2006; Bharadwaj and Novotny, 2007; Hartling, et 
ai., 2007]. Bharadwaj and Novotny [2007] expressed this model in a more explicate way: 
Y:m = [Y:,c] [:], 
Yem Yexc q 
(9) 
where Yem is the emission decay rate, Yexc is the excitation rate, and q is the quantum 
yield, and the superscript ,0, denote the values without the particle. Following to the 
Fermi's Golden Rule [Fermi 1950], the excitation decay rate below the optical energy 
saturation can be expressed in terms of E2: 
Y:xc = 1 Eo 12 
Yexc E 
(10) 
The intrinsic quantum yield of the fluorophore (qO) is defined to be 
o 
qo = Yr 00' 
Yr + Ynr 
(11) 
where yO and Y~r are the radiative decay rate and non-radiative decay rate of the 
r 
fluorophorewithout the particle, respectively. When the fluorophore is placed In a 
plasmon field, both radiative decay rate and non-radiative dacay rate changed. 
The expression of the radiative decay rate, Yr , is derived by computing the 
radiative power induced by the particle using the polarizability of the particle [Gersten 
and Nitzan, 1981; Bharadwaj and Novotny, 2007]. Fora spherical particle without 
coating, in vacuum, with quasi-static polarizability, they found 
(12) 
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This expression for y,/ y; is identical with the IE/ EOl2 for the particle in vacuum, at 8=0, 
and with incident light frequency of WI. 
The particle also changes the non-radiative decay rate of the fluorophore by 
adding an additional non-radiative decay rate (y tlb.J This rate can be deduced from the 
power that is radiated by the fluorophore and absorbed by the particle (for us, GNP). 
Using the electrostatic image theory [Novotny and Hecht, 2006], the power emitted by 
the fluorophore and absorbed by the particle inside a half-space can be calculated by 
integrating the dissipated power density, and the energy transfer rate becomes 
(13) 
where WI is the emission light frequency, c is the speed of light and p = [Px,Py,Pz] is the 
transition dipole moment. At 8=0, 
(14) 
The intrinsic non-radiative decay rate can be written as y::r = y;. (1- qO ) / qO. This 
accounts for nonradiative losses inside the fluorophore only, i.e., it is an intrinsic property 
of the fluorophore. The quantum yield of a fluorophore affected by the particle then 
becomes [Bharadwaj, et ai., 2007] 
lJ= fo If) 00 




In summary, for a selected fluorophore, when the particle size, the coating 
material and the distance between a fluorophore and a particle are known, the 
fluorescence change by the particle can be estimated using Eqs 1-15. 
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Angers, et al. [2006] and Bharadwaj and Novotny [2007] have used this theory to 
compute the fluorescence alteration of a fluorophore Nile Blue and a single GNP (60 nm). 
Their theoretical results correlated well with the experimental results. Cheng, et aI., [2011] 
used DNA strands of various lengths to control the distance between a fluorophore and a 
GNP of various sizes, and their experimental results also matched well with the 
theoretical prediction using the model. 
(b-ii) Quantum mechanical model 
Gersten and Nitzan [1981] have developed a quantum mechanical model that 
considered the system with the molecular dipole and the particle's plasmons. The model 
provides the Hamiltonian and the equations of motion for the system in the presence of 
the incident radiation field. However, the model is limited to the case when the distance 
between the fluorophore and the particle is greater than the radius of the particle [(r-
r 1 »r 1]. Vukovic, et al. [2009] also developed a model using quantum mechanics. The 
model considers the chemical structure of the fluorophore, instead of using a point-dipole 
approximation, and is not limited to single particle, but can address a variable number of 
particles. 
The relative brightness, qJRB is determined by 
(16) 
where q is the quantume yield of the fl uorophore as described in Eq. (11), A free is the 
molecular absorption coefficient in the absence of the particle. The ratio AIAFee accounts 
for the different population in the excited state induced by the particle on the molecular 
absorption. This equation actually has the same physical meaning as in Eqs. (8) and (9). 
While in computing radiative (Yr) and non-radiative decay rate (Ynr) and the absorption 
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coefficient (A), the particle is considered as a continuous dielectric characterized by the 
optical constants and the fluorescence is treated quantum-mechanically [Corni, et aI., 
2002; Andreussi, et ai., 2004]. The model belongs to a family of the polarizable 
continuum model (PCM) [Tomasi, et ai., 2005]. The fluorophore is described by an 
effective Hamiltonian. The electrostatic interaction energy between the molecular charge 
density and the polarization of the particle is induced by the molecular charge density 
itself. These charges are obtained by the boundary element method solution of the 
integral equation formalism approach to the Poisson problem [Vukovic, et aI., 2009]. 
The absorption coefficient, A, is given by 
(17) 
where h is the Dirac constant, n is the refractive index of the medium, and "KO is the 
transition dipole between the ground state and the Kth excited state, and it is directly 
affected by the interaction with the particle (metal) and the solvent: 
-mol -met -sol 
fLKo = fLKO + fLKO + fLKO ' (18) 
-mol -met -sol 
where fLKO is the molecular transition dipole, fLKO and fLKO are the transition dipole 
effect of the particle and the solvent, respectively. 
The radiative decay rate (yJ and non-radiative decay rate (Ynr) are 
(19) 
Ynr = -2 Im( P ) , (20) 
where P is the excitation energy. 
Vokuvic, et ai. [2009] used this model (Eq. 16-20) to compute the fluorescence of 
N,N'-dimethylperylene-3,4,9,1O-dicarboximide in combination with silver and gold 
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nanoparticles, and the results account for continuous change from quenching to 
enhancement. However, there have not been many experimental verifications of this 
model. 
D. NANOPARTICLES FOR BIOMEDICINE 
In 1959, Richard Feynman introduced the concept of nanotechnology in his 
pioneering lecture titled "There's plenty of room at the bottom" at the annual meeting of 
the American Physical Society [Appenzeller, 1991]. However, nanotechnology has 
become a rapidly growing field only in the recent decade. The term "nanotechnology" 
varies greatly based on the specific definition that is used. The U.S. National Science 
Foundation and the National Nanotechnology Initiative define the nanotechnology as 
understanding and control of matter at dimensions of 1-100 nm, where unique 
phenomena enable novel applications [Khademhosseini and Langer, 2006]. 
1. Advantages of nanoparticles for biomedical application 
Nanotechnology is an emerging field that would potentially make a major impact 
to human health [Khademhosseini and Langer, 2006]. Living organisms are built of cells 
that are typically in the range of 10 !Am. However, the cell parts are much smaller and are 
in the sub-micron size domain. The proteins are even smaller, with a typical size of 5 nm. 
This size comparison reveals that using nanoparticles as probes would allow us to 
understand the cellular machinery at a molecular level, without introducing too much 
interference [Taton, 2002; Salata, 2004]. Understanding of biological processes on a 
nanoscale level has been a strong force behind the development of nanotechnology 
[Whitesides, 2003]. 
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The small size of nanoparticles makes them suitable for bio-tagging or labeling. 
The surface of a nanoparticle can be conveniently used for a molecular assembly. The 
molecules are usually one or more than one of the following: The small molecules that 
make the particle biocompatible, antibodies/aptamers/peptide for biomolecule detection 
or in vivo targeting, fluorophores for signaling, drugs for disease treatment, etc. Since a 
particle can carry more than one function in a single entity, multifunctionality is a 
fundamental characteristic of nanoparticles [Salata, 2004; Singh, et at., 2009]. Studies 
have also shown that nanoparticles feature a longer circulation time in blood, higher 
uptake rate by cells [Davis, 2008] and a high concentration of drug in/around them 
[Ferrari, 2005]. In addition to these general advantages, many nano-materials exhibit 
unique properties, e.g., optical, magnetic properties, etc., which can be beneficially 
utilized for biomedicine. 
These advantages and special properties of nanoparticles have made nano-
medicine a booming research area, especially in cancer diagnosis and therapy. During the 
past decades, advances in cancer biology have not been translated into medicine 
appropriately, mainly due to the inability of administering contrast agents and therapeutic 
moieties selectively to the desired targets [Langer and Tirrel, 2004; Ferrari, 2005]. 
Nanomaterials may be, therefore, excellent candidates for overcoming these issues. 
2. Types of nanoparticles 
Most of the nanoparticles currently being developed for medical use may be 
classified into two: i.e., particles of organic molecules mainly and those with the 
inorganic element, usually metals, as the core. 
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(a) Organic nanoparticles 
Organic nanoparticles including liposomes, dendrimers, and other bio-polymers 
are being developed for drug delivery to various human tumors, including breast cancer 
[Park, 2002; Hofheinz, 2005]. The first nano-vehicle for drug delivery is liposome. As 
other nanoparticles, liposomes feature longer circulation time especially when the surface 
is modified with PEG. With the leaky nature of the cancer neovasculature, they may have 
a significant selectivity in drug delivery to tumors [Papahadjopoulos, et aI., 1991; Oku 
and Namba, 1994]. Liposome-encapsulated formulations of doxorubicin were approved 
in the 1990s for the treatment of Kaposi's sarcoma, and are now used to treat breast and 
refractory ovarian cancer. Liposomes continue to be refined and applied to more cancer 
types [Langer and Tirrel, 2004; Allen, 2002; Park, 2002; Kircher, et al., 2003; Ferrari, 
2005]. 
Dendrimers and various bio-degradable polymers, such as poly(lactic acid) (PLA), 
poly (glycolic acid) (PGA), poly (lactic co-glycolic acid) (PLGA) and polyanhydride are 
also being studied to encapsulate drugs. The particles can be designed to release drugs 
through the bulk erosion, diffusion, or being triggered by the external environment, such 
as changes in pH, light, temperature or by the presence of certain biomolecules 
[Khademhosseini and Langer, 2006; Langer and Tirrel, 2004]. They can also be used to 
encapsulate highly toxic, poorly soluble or relatively unstable drugs whose clinical use 
was limited without using nano-capsules [Langer, 1998]. These particles may also 
include disease-targeting molecules for targeted delivery. 
In addition to the drug delivery, nanotechnology has contributed to advance in 
medical techniques, such as implantable nanoporous membranes [Tao and Desai, 2003], 
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controlled release biochips [Santini, et ai., 1999], and transdermal microneedle systems 
[Prausnitz, et ai., 2004]. New organic nanoparticles are still being discovered and 
characterized, providing potential future applications. 
(b) Inorganic nanoparticies 
Inorganic nanoparticles are usually a metal or metal compound possessmg 
medically beneficial properties, including size-dependent physical properties, optical and 
magnetic effects [Salata, 2004]. 
(b-i) Gold nanoparticies 
Noble metal nanoparticles, such as gold and silver, possess umque optical 
properties. In biosensing, for years, gold and silver nanoparticles have been used in 
surface-enhanced Raman scattering (SERS). The sensitivity enhancement factor of SERS 
is as high as 1014_10 15 , which improves the detection limit [Boisselier and Astruc, 2009]. 
GNPs are used to develop biosensors utilizing the surface plasmon peak shift by their 
surface or environment change, such as the binding of analytes onto GNP surface 
conjugated with the recognition molecule, the inter-particle distance changes when GNPs 
bind to each other via the molecules conjugated on the surface [Jain, et aI., 2008]. 
For bioimaging, GNPs are also studied for many other imaging modalities: Large 
GNPs (>20 nm) can be imaged using an optical microscope in the phase contrast or 
differential interference contrast mode [Boisselier and Astruc, 2009]. Small GNPs absorb 
light and generate heat which can be detected via the local variation of the refractive 
index using Differential Interference Contrast (DIC) microscopy or via the heat-induced 
liquid expansion using photoacoustic imaging [Boisselier and Astruc, 2009]. GNPs can 
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also be used in optical coherence tomography (OCT), which is an optical analogue to 
ultrasound with a relatively good resolution (1-10 !lm) [Skala, et aI., 2008]. GNPs 
generate an enhanced signal for the multi photon surface plasmon resonance (SPR) 
microscopy when they are illuminated at their resonance frequency [Yelin, et aI., 2003]. 
They also generate better contrast in X-ray scattering than the organic contrast molecules, 
providing high signal-to-noise ratio for the X-ray and X-ray computer tomography 
[Hainfeld, 2006; Cai, et ai., 2007; Kim, et at., 2007]. GNPs are also studied to enhance 
gamma radiation using neutron activation [Sperling, et at., 2008]. 
For medical therapies, GNPs are studied for optical cancer hyperthermia 
(photothermal therapy) [Boisselier and Astruc, 2009]. GNPs have high absorption cross 
sections requiring less irradiation energy and the irradiation via the SPR of GNPs 
converts energy from light to heat fast [Hirsch, et ai., 2003; O'Neal, et aI., 2004; Loo, et 
aI., 2005; Huang, et ai., 2006]. NIR is desired for its deep penetration into tissue and the 
small GNPs (10-30 nm) forming larger clusters absorb NIR light (700-1000 nm) well 
[Zharov, 2005]. Gold nanoshells and nanorods that absorb light in NIR are also 
extensively studied for this purpose [Hirsch, et ai., 2003; Loo, et ai., 2005]. 
GNPs are typically synthesized by reduction of chloroauric acid [H(AuCI4)] using 
citric acid. They are stabilized by citric acid, but not stable in solutions with a high ionic 
strength. GNPs for biomedical uses require high stability in physiological conditions, 
while maintaining their optical properties. Stability, from a biological point of view, 
means good solubility and dispersivity in the physiological environment, as well as the 
cellular or molecular interaction [Duchesne, et aI., 2008]. The solubility can be achieved 
by coating the GNP surface with a stable and biocompatible hydrophilic shell. 
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Shell materials that have been frequently used are the polymeric capping agents, 
such as, amino- or mercapto-dextrans or polyethylene glycol (PEG) (Fig. 3a) and the 
thiol ligands with hydrophilic end groups, which form a self-assembled monolayer 
(SAM); (Fig. 3 b) [Duchesne, et al., 2008]. Compared to the arbitrary polymer coating, 
the SAM provides important advantages. The thickness of the coating layer may be kept 
minimal, which is particularly important for our study with spacers of a short length. It 
avoids the steric hindrance of the GNP during penetrating into cells or synapses. 
(a) (b) 
Figure 3. GNP stabilized with (a) large polyethylene glycol molecules and 
(b) with small aliphatic-PEG molecules 
A number of SAM ligand shells have been developed, and they usually follow a 
basic design composed of a hydrophobic chain (aliphatic chain), allowing tight packing 
of the monolayer, and a hydrophilic terminus to provide solubility in physiological 
environments [Duchesne, et aI. , 2008 ; Pciotti, et aI. , 2006; James, et aI. , 2007]. The most-
used materials for the hydrophilic terminus are PEGs, because PEG layer provides the 
GNPs with excellent hydrophilicity to the particle, and it minimizes the adsorption of 
particles to proteins [Ostuni, et aI. , 2001]. 
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(b-ii) Magnetic nanoparticie 
Magnetic nanoparticles (MNP) have recently attracted attention because of their 
ability of increasing contrast for MRI and cancer hyperthermia. Iron oxide nanoparticles 
(Fe304, Fe203) are the most explored for these purposes. When the ferrite nanoparticles 
become smaller than 128 nm they become superparamagnetic, which prevents self-
agglomeration because they exhibit the magnetic property only when the magnetic field 
is applied [Weissleder, et al., 1990]. They were found to have much greater magnetic 
susceptibility than traditional MR contrast agents, such as gadolinium [Cuenca, et aI., 
2006]. They have rapid hepatic uptake after intravenous administration, which makes 
them useful for the characterization of hepatic tumors [Ferrucci and Stark, 1990]. 
Ultrasmall-superparamagnetic iron oxide nanoparticles (SPIONs; 5-10 nm) may have 
better tissue distribution, allowing uptake in lymph nodes and bone marrow [Weissleder, 
et aI., 1990]. They have been used therefore, clinically in human for characterizing lymph 
node status in patients with cancers [Cuenca, et aI., 2006]. 
MNPs can be heated in an alternating electro-magnetic (AEM) field, by hysteresis 
loss, Neel relaxation, orland Brownian relaxation [Hergt, et aI., 1998]. Therefore, they 
are extensively studied for localized cancer hyperthermia [Jin, et aI., 2006; Kumar and 
Mohammad, 2011]. Compared to the traditional hyperthermia treatment, MNPs can be 
targeted for the cancer by using the disease-specific binding agents, making the treatment 
tumor.-specific. The AEM frequencies utilized are harmless to the body and generate heat 
only in the tumor containing MNPs [Rand, et aI., 1985]. This hyperthermia method can 
be combined with controlled delivery of drugs, utilizing heat-induced bond-breaking 
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between drug and polymer on the MNP, heat-enhanced permeability of the drug from the 
polymer to the tumor, etc. [Kumar and Mohammad, 2011]. 
Paramagnetic nanoparticles have also been used in concentrated drug delivery to 
tumors [Cuenca, et ai., 2006]. Alexiou, et ai. [2000] used magnetic fields to concentrate 
methotrexate-conjugated nanoparticles in tumor to focus greater amounts of the drug in 
the desired areas, while being able to lower the systemic or intra-arterial concentration. 
This drug delivery system was translated into a Phase I clinical trial and demonstrated 
better patient tolerance of therapy with the successful localization of nanoparticles to the 
tumors but with no magnetic field-associated toxicities [Lubbe, et ai., 1996]. 
Nanoparticles with a magnetic core, either of elementary Iron or Cobalt, with 
nonreactive shell have been synthesized recently for biomedical research application 
[Grass and Stark, 2006]. Magnetic CoPt nanoparticles and iron-oxide-based magnetic 
materials have been used in clinical practice as contrast agents for MRI [Meng, et ai., 
2011]. 
MNP may also be coated with a gold layer to incorporate the optical properties of 
gold and achieving multi-functions for disease diagnosis and treatment [Chen, et ai., 
2003]. 
In general, nanoparticles features numerous advantages that can be beneficially 
applied to biomedicine. Although this study focuses only on the unique phenomenon of 
fluorescence manipulation by GNP, the GNP can be a platform to incorporate many other 
beneficial functions in the future. 
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E. FLUORESCENCE ALTERATION BY GNP, PREVIOUSLY STUDIED BY 
THE KANG GROUP 
The Kang group has been studying the application of GNPs for fluorophore-
mediated biosensing and bioimaging since 2005. Hong and Kang [2006] applied GNPs to 
a fiber-optic immuno-biosensing system to increase its sensitivity. The sensor performs a 
fluorophore-mediated sandwich immunoassay on the sensor surface, and the fluorescence 
intensity is correlated with the analyte concentration [Kang et a!., 1997; Spiker et a!., 
1998]. Fluorolink Cyanine 5 (Cy5, Ex/Em 647/679 nm) and Alexa Fluor 647 (AF647; 
Ex/Em 649/666 nm) were used as the fluorophore. To adjust the distance between the 
free GNP and fluorophores in solution, self-assembled monolayers (SAMs) at various 
thicknesses were coated on the gold particle surface. The effect of GNP size and the 
SAM thickness on fluorescence enhancement was studied. . 
Hong and Kang [2006] also found that some solvents can enhance the 
fluorescence of a fluorophore, by shifting the fluorophore excitation/emission 
wavelengths [Buschmann, et a!., 2003], and/or by changing the trans-cis isomerization 
direction [Aramendia, eta!., 1994; Scaffardi, eta!., 1997; Rodriguez, eta!., 1997], and/or 
by shrinking proteins if fluorophores are tagged to them [Bonincontro et al., 1997; 
Ruckebusch et a!., 1999]. They have found that I-butanol and ethanol gave high 
enhancement without denaturing the antibodies immobilized on the sensor surface. To 
maximize the enhancement effect, the two enhancers, the GNP-SAM and the solvent 
were mixed to form GNP reagent (GNPR). Hong, et a!. [2006] and Wang, et al. [2008] 
applied the GNPR in Alexa fluorophore (Alex-647) mediated four-cardiac marker 
sensing system to be used for real-time diagnosis of acute myocardial infarction. By 
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using GNPR, the size of the sensors was reduced from 3 cm to 1.5 nm, enabling a 
portable, mini-sensing chip (2 x 2.5 cm), and this system can accurately quantify four 
cardiac markers simultaneously at clinically significant concentration range within 15 
min, requiring a plasma sample volume of only 200 [!l. 
In biosensing the distance between the GNP and the fluorophore may not be 
precisely controlled because only the minimum distance between these two may be 
controlled by the thickness of the SAM. The distance may also be strongly affected by 
the GNP concentration, because the reagents are confined in a small sensing channel 
[Wang, et ai., 2008]. However, this problem may be resolved by testing the agent for the 
controlled sensing protocal. 
Unlike in the biosensing, for bioimaging in vivo, the fluorophore needs to be 
physically linked to the GNP and the distance between the GNP and the fluorophore 
needs to be well controlled. Kang, et al. [2011] have studied the fluorescence change of 
an NIR fluorophore, Cypate, with changing the distance from a 10 nm GNP. The distance 
was controlled by coating a polymer layer at known thickness on the GNP. Cypate was 
placed on the outermost layer of the polymer coated GNPs, artificially separated from the 
GNP at the distance of the polymer layer thickness, and its fluorescence levels were 
observed. The fluorescence of Cypate on the particle surface was quenched almost 
completely and, at approximately 5 nm from the surface, it was enhanced -17 times. 
Then the level went down thereafter. This study experimentally suggested the 
relationship between the level of Cypate fluorescence alteration and the distance from a 
GNP. 
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To have a thorough understanding of fluorescence alteration by GNP, this 
dissertation theoretically studies the fluorescence of various fluorophores affected by 
GNPs. In addition, experimentally, a novel, highly specific and sensitive contrast agent 
for bioimaging is developed utilizing fluorescence alteration by GNP. 
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CHAPTER III 
MATERIALS, INSTRUMENTS, AND METHODS 
A. THEORETICAL STUDY 
The fluorophores selected for our study are the ones frequently used in biomedical 
studies and at various EmlEx wavelengths. They are Fluorescein isothiocyanate (FITC), 
Alexa Fluor 532 (AF532), Cyanine 3 (Cy3), Alexa Fluor 647 (AF647), Alexa Fluor 700 
(AF700) and Indocyanine Green (ICG). The fluorophores, their ExlEm peak wavelengths 
and intrinsic quantum yield values are listed in Table 1. 
Table 1. Fluorophores studied, and their excitation/emission peak 
wavelengths and intrinsic quantum yields. 
Fluorophore Excitation peak Emission peak qO 
wavelength (nm) wavelength (nm) 
FITC 494 521 0.93 
AF532 530 555 0.61 
Cy3 550 570 0.15 
AF647 650 665 0.33 
AF700 702 723 0.25 
ICG (Cypate) 780 830 0.012 
Solutions for the mathematical model were computed using Matlab R200Sa (The 
Mathworks Inc., Natick, MA). The dielectric permittivity values used in the plasmon 
field strength computation are: for GNPs, the experimental data by Johnson and Christy 
[1972] were used; for the shell, value for polyethylene glycol (PEG), 2.S5 t{" was used, 
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where Eo is the dielectric constant of vacuum, 8.85 x 10-12 C2/N m2• For the surrounding 
medium, water, the E3 value of 1.76 Eo was used. 
B. SYNTHESES OF SPACERS AND MODIFICATION OF CYP ATE 
In this section, the materials, instruments and methods of making the spacers. 
SSP-Cy and m-Cypate are presented. 
The molecular spacers tested for Cypate fluorescence alteration were synthesized 
by the Nantz group at the University of Louisville or by the NeoGroup Inc. (Cambridge, 
MA) through customized peptide synthesis, with our design. The detailed structures of 
the spacers are listed in Table 2. 
Table 2. Molecular spacers used for conjugating Cypate to GNPs. 
Catagory Structure Abbreviation Producer 
SH-(CH2h-Gly-Gly-Arg-Gly-Gly-Gly-NH2 SSP The Nantz group Short spacer 
SH-(CH2}z-Gly-Gly-Arg-Gly-Gly-Gly-ONH2 nSSP 
HS-(CH2)12-(OCH2CH2)4-0NH2 LSP (CI2PEG4) 
HS-(CH2)lr(OCH2CH2)6-0NH2 LSP (CI2PEG6) 
Long spacer HS-(CH2)12-(OCH2CH2)s-ONH2 LSP The Nantz group (C12PEG8) 
HS-(CH2)16-(OCH2CH2)4-0NH2 LSP (C16PEG4) 
HS-(CH2)16-(OCH2CH2)6-0NH2 LSP (CI6PEG6) 
Dual spacer cyclo[DAP(Aoa)-PEG5-(8-aminooctanoic rDSP NeoGroup Inc. 
ac id )-Cys-G ly -Arg-G ly-G ly -G ly] * 
* The molecular structure of rDSP is shown in Fig. 33. 
To enable the oxime coupling of Cypate to the nSSP and LSPs, The Nantz group 
added aldehyde groups to the Cypate (modified-Cypate; m-Cypate). 
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B-1. MATERIALS 
Polystyrene resin and amino acids used in the synthesis of short and long spacers 
were purchased from Novabiochem (San Diego, CA). The coupling agents, 3-
(diethoxyphosphoryloxy )-1 ,2,3-benzotriazin-4(3H)-one (DEPBT), hydroxybenzotriazole 
(HOBt), N,N-Diisopropylethylamine (DIPEA), CH2Ch, trifluoroacetic acid and 
triethylsilane were obtained from Aldrich (St. Louis, MO). All other materials were 
purchased from Sigma Aldrich (St. Louis, MO), unless otherwise specified. 
Cypate (Cy) was produced and supplied by The Achilefu group at the Department 
of Radiology, Washington University School of Medicine, St. Louis, MO [Achilefu, et 
at., 2002; Ye, et at., 2003]. 
B-2. INSTRUMENTS 
For purifying the spacers after each reaction silica gel flash column 
chromatography (Teledyne ISCO; Lincoln, NE) was used. Solvent evaporation was done 
using a bench top solvent purifier SPBT-1 (LC Technology Solutions, Inc.) Synthesized 
SPs was analyzed by HPLC (Waters Corporation Delta 600 instrument; Waters corp.; 
Milford, MA) and high-resolution mass spectrometry (HRMS; L TQ FT Ultra mass 
spectrometer; Thermo Scientific; Waltham, MA) with TriVersa NanoMate system 
chipbased infusion (Advion Biosciences, Inc.; Ithaca, NY). 
The theoretical length estimations of the spacers and other molecules were done 
using the computer software Hyperchem 7.5 (Hypercube Inc.; Gainesville, FL). 
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B-3. METHODS 
The methods described in this section are the revised version of the project report 
from the Nantz group. 
(a) Synthesis of the short spacers 
The short spacer, HS-CH2-CH2-G-G-R-G-G-G-NH2 (SSP) was synthesized using 
standard solid-phase peptide synthesis techniques [Merrifield, 1963]. For HS-CH2-CH2-
G-G-R-G-G-G-ONH2 (nSSP), the HS-CH2-CH2-G-G-R-G-G-NH2 was synthesized 
following the same methods used for SSP. Then 100 mg of the resin loaded with it was 
swelled using Dimethylformamide (DMF) over 30 mins, filtered, and then treated with 
0.21 mmol Fmoc-protected aminooxyglycine, 0.21 mmol DIC, 0.21 mmol 
Hydroxybenzotriazole (HOBt) and 0.42 mmol Diisopropylethylamine (DIPEA) in 2 mL 
of DMF. After shaking the mixture overnight, the resin was filtered and then thoroughly 
washed with CH2Ch 7 times. The resin was dried under vacuum, swelled using 
dimethylformamide, filtered, and then treated with 20% piperidine in 3 ml DMF at room 
temperature for 40 mins. The piperidine washing process was repeated once. The resin 
was filtered and washed successively with DMF for 3 times and with CH2Ch for 5 times, 
and then dried under vacuum. 
(b) Conjugation of Cypate to SSP 
0.227 mmol Cypate was added to the HSCH2CH2NH-G-G-R-G-G-G-NH2-loaded 
resin (65 mg, 0.045 mmol peptide) in DMF at room temperature. 0.227 mmol DEPBT, 
0.227 mmol HOBt, and 0.45 mmol DIPEA were added as coupling agents. After shaking 
the mixture overnight, the resin was filtered and thoroughly washed with CH2Ch 7 times. 
The resin was then dried under vacuum. To the HS-CH2-CH2-NH-G-G-R-G-G-G-
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NHC(O)-Cypate resin prepared above (15 mg, 0.01 mmol) in 0.3 mL ofCH2Cb, 0.06 mL 
of triethylsilane was added at room temperature. After shaking the mixture for 15 min, 
0.04 mL of trifluoroacetic acid was added and the resin suspension was shaken for 1 hr, 
allowed to stand for 1 hr, and then shaken for 3 hrs. The resin was filtered and the filtrate 
was concentrated by rotary evaporation. The residue was washed with diethylether for 5 
times and dried under vacuum to obtain the target cysteamine-hexapeptide-cypate (SSP-
Cy) conjugate. The conjugates were characterized with HRMS (FrICR). 
(c) Synthesis of long spacers 
Scheme 1 illustrates the procedure for the synthesis of HS-(CH2)12-(OCH2CH2)s-
ONH2, as an example of the synthesis of long spacers. 
Br~OH 
(1) ~ (2,3) ~ 






Scheme 1. Synthesis route of the spacers 
The sequence number in the content before corresponds to the numbers in Scheme 1. 
(1) 7.56 mmol Potassium carbonate was added to a solution of 3.78 mmol 12-bromo-
dodecanol in methanol, at room temperature. After stirring it for 5 minutes, 4.90 
mmol triphenylmethanethiol (TrS) was added, and then the mixture was stirred 
for 16 hours. It was then diluted with diethyl ether and neutralized with 
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Na2HP04/NaH2P04 buffer. The buffer was removed, and the organic layer was 
washed with NaCI brine 3 times. The aqueous layers were combined and 
extracted with diethyl ether, dried over Na2S04 and concentrated by rotary 
evaporation. The crude residue [TrS-(CH2)I2-0H] was purified by flash 
chromatography. 
(2) 30 mL dry CH2Ch was added to a N2 purged flask containing 1.95 mmol 
TrS(CH2)120H and equal mole of sodium bicarbonate. 
(3) 4.88 mmol carbon tetrabromide and 5.07 mmol triphenylphosphine in minimal 
dry CH2Ch were added, and stirred for 12 hours. The resulting solution [TrS-
(CH2)12-Br] was washed, extracted, dried and purified as described in the step (1). 
(4) 6.18 mmol tetra(ethylene glycol) in DMF was added to 12.17 mmol sodium 
hydride in DMF, at ODC under N2. After 5 minutes, 1.03 mmol TrS(CH2)12Br in 
DMF was added, and then allowed to reach room temperature and stirred under 
N2 for 72 hours. The product [TrS-(CH2)12-(OCH2CH2)s-OH] was then washed, 
extracted, dried and purified. 
(5) 0.414 mmol N-hydroxyphthalimide and the same mole of triphenylphosphine 
were added to 0.345 mmol TrS-(CH2)12-(OCH2CH2)s-OH in dry THF, under N2 at 
ODC. Then 0.414 mmol diisopropyl azodicarboxylate was added dropwise. The 
solution was warmed to room temperature and stirred overnight. The mixture was 
concentrated by rotary evaporation, and washed, extracted, dried and purified 
[TrS( CH2) 12-(OCH2CH2)s-ONPhth]. 
(6) 3.35 mmol hydrazine monohydrate was added to a solution of 0.168 mmol 
TrS(CH2)120PEGsONPhth in CH2Ch, at room temperature, and the mixture was 
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stirred for 3 hours. The product [TrS(CH2)12-(OCH2CH2)g-ONH2J was dried by 
rotary evaporation and purified by flash chromatography. 
(7) Excessive amount of trifluoroacetic acid and 0.073 mmol triethylsilane were 
added to a solution of 0.123 mmol TrS(CH2)120PEGsONH2 in CH2Ch, at room 
temperature and the mixture was stirred for 3 hours under N2. The product [HS-
(CH2)12-(OCH2CH2)s-ONH2J was dried by rotary evaporation and vacuum 
pumping, and then purified by flash chromatography. 
Other spacers, HS-(CH2)n-PEGm-ONH2 for n=12 and 16, and m=4 and 6, were 
synthesized following the same procedure. Each product was analyzed and confirmed 
by HPLC and HRMS. 
(d) Modification of Cypate 
In this reaction, (C2HsOhCH(CH2hNH2 was conjugated to the two -COOH 
groups of Cypate via the amine-carboxylic acid reaction, and the -CH(OC2HSh group 
was then modified to -CHO. 
(1) 0.48 mmol amino acetal (C2HsOhCH(CH2hNH2 was added to a mixture of 0.12 
mmol Cypate, 0.48 mmol HOBt, and 0.48 mmol EDC in 2 mL dry DMF, at room 
temperature, and the mixture was stirred overnight in dark, at room temperature. 
(2) The step (1) was stopped by adding water, and the product [Cypate conjugated 
with two molecules of (C2HsOhCH(CH2)3NH2J was extracted using CH2Ch. The 
organic layer was washed with brine and then dried with Na2S04. The solvents 
were removed by rotary evaporation and the residue was purified by column 
chromatography (Si02, eluting with a gradient of 1-7% methanol in CH2Ch). 
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(3) The product was hydrolyzed by dissolving it at 1.6 mg/ml in 30% aqueous acetic 
acid, with stirring for 3.5 h at room temperature. The solvent was then removed 
under vacuum to obtain aldehyde-Cypate (modified Cypate; mCy) as a green 
solid. 
C. CONJUGATION OF CYPATE TO GNP 
C-l. MATERIALS 
Gold nanoparticles (GNPs; 5, 10, and 15 nm according to the manufacture's 
information; 3.7, 8.0 and 16.4 nm by our measurement) stabilized with citric acid and 
tannic acid in aqueous solution were purchased from Ted Pella (Redding, CA). 
The GNP coating material (I-Mercapto-ll-undecyl) tetra( ethylene glycol) [HS-
(CH2)w(CH2CH20h; MW, 380.58; sPEG] was from Asemblon (Redmond, W A) or 
ProChimia Surfaces (Ul. Zacisze, Poland). 
Urokinase-type plasminogen activator (uPA) was purchased from Innovative 
Research (Novi, MI). 
Pure argon was provided by Welders Supply (Louisville, KY) to blow-dry the 
substrate; ethanol, dimethyl sulfoxide (DMSO) and all other chemicals were from Sigma-
Aldrich, unless otherwise specified. 
C-2. INSTRUMENTS 
For GNP purification after conjugation, dialysis was done with Slide-A-Lyzer 
Dialysis Cassettes (20K MW Cut-Off; Thermo Scientific; Rockford, IL). Centrifugation 
was done using Eppendorf 5415 R Centrifuge (Eppendorf AG; Hamburg, Germany). A 
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sonicator (Sonic Dismembrator; Fisher Scientific; Chicago, IL) was used to disperse 
GNPs pellet in solutions after centrifugation. 
For characterizating various GNP products, absorption spectra were used 
(Beckman DU520 spectrometer; Beckman Instruments, Inc.; Fullerton, CA). The size of 
GNPs before and after the surface modification was measured by a dynamic light 
scattering (DLS) particle size analyzer (90PlusIBI-MAS; Brookhaven Instruments Co.; 
Holtsville, NY) and a transmission electron microscope (TEM; Tecnai™ HR FEG-TEM; 
FEI co.; Hillsboro, Oregon). 
Fluorescence was measured by the Spectra Gemini XPS fluorometer (Molecular 
Devices Corp.; Sunnyvale, CA) in the 96-well Uniplate (Whatman; Florham Park, NJ) at 
the excitation and emission wavelengths of 780 and 830 nm, respectively. 
C-3. METHODS 
(a) Handling of thiolated materials: 
The GNP surface coating materials (sPEG) and all spacers (SSP-Cy, nSSP, LSPs, 
and rDSP) reacting to GNPs contain a thiol ending, which can be oxidized easily by 
oxygen in the air. Therefore, special care is required in handling these spacers. The 
spacers were received in a solid form at room temperature. To dissolve the spacers 
ethanol was first purged with argon. The spacers were dissolved at a concentration of -5 
mg, and the solution was divided into small aliquots, sealed in containers under argon, 
and kept at -70°C for a short-term « 2 month). For a long-term storage, the spacer was 
blow-dried with argon to form a solid and the container was sealed under argon, and kept 
at -70°C. 
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Pure sPEG is solid at 4°C and becomes liquid at room temperature. At room 
temperature it is made into small aliquots and then kept under argon, at 4°C as a solid as 
suggested by the manufacture. Before each use, sPEG was warmed to room temperature 
and 2 !!L of sPEG was taken and dissolved in 500 !!L ethanol, forming stock solution at 
3.4 mglmL (9390 !!M). 
(b) GNP surface modification and Cypate conjugation 
(b-i) Conjugation of SSP-Cy to GNP 
SSP-Cy and sPEG were conjugated to GNP following the procedure described 
below: 
(1) SSP-Cy and sPEG were mixed at a molar ratio of 1:4 and diluted in ethanol in a 
volume equal to the volume of the GNP solution to be added, to result in a 1: 1 
(volume ratio) ethanol and water mixture. 
(2) The colloidal GNP solution was added to the SSP/sPEG mixture and the mixture 
was stirred for 4 hrs at room temperature. According to Duchesne, et al. [2002], a 
tightly packed, mixed monolayer of sPEG and peptide on the GNP surface 
corresponds to 3.6 molecules/nm2-GNP surface area. Here, the amount of SSP-Cy 
and sPEG was at 60 molecules/nm2-GNP surface area (excess by 15 times). 
(3) After the reaction, the solution was placed in a dialysis cassette and the cassette 
was placed in 2 L of de-ionized (D!) water in dark with stirring overnight. 
(4) The dialyzed sample was then centrifuged at 13000 RPM for 60 min. The pellet 
was re-dispersed in 1 mL of D! water and sonicated for 5 minutes. 
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(5) The GNP and Cypate in the solution were quantified by their respective 
absorption peaks (520 and 780 nm, respectively). 
(b-ii) Conjugation of nSSP to GNP! Conjugation of mCy to nSSP on GNP 
nSSP and sPEG were first reacted onto GNP and purified, and then m-Cypate was 
reacted to GNP-nSSP: 
(1) nSSP and sPEG were mixed at a ratio of 1:4 and diluted in ethanol by the same 
method described in step (1-3) of (b-i) above. 
(2) The GNP was quantified by the light absorption at 520 nm. 
(3) mCy was dissolved in ethanol at 2.5 mM; a blocking agent, Me3N+-(CH2h-ONH2 
(BLK) was added to mCy solution at a 1: 1 molar ratio and reacted in dark, at 
room temperature, overnight. Addition of BLK is to block one of the two reactive 
-CHO groups of mCy, and increases the hydrophilicity of mCy. 
(4) mCy-BLK was added to the solution from step (2) at 0.3 molecule/nm2-GNP 
surface and reacted with stirring, for 4 hrs, in dark, at room temperature. 
(5) The solution from step (4) was dialyzed using the cassette in 2 L of DI water with 
stirring, in dark, overnight. 
(6) The dialyzed sample was then centrifuged at 13000 RPM for 60 min. The pellet 
was re-dispersed in 1 mL of DI water and sonicated for 5 minutes. 
(7) The GNP and m-Cypate in the solution were quantified spectroscopically. 
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(b-iii) Conjugation of m-Cypate to GNP via long spacers (LSP) 
LSP and sPEG were first reacted onto GNP and purified, and then m-Cypate was 
reacted to GNP-LSP. 
(1) Colloidal GNP solution was concentrated -10 times by centrifugation at 13,000 
RPM for 60 mins; 
(2) The GNP concentration was determined by the absorption at 520 nm; 
(3) To avoid aggregation of the GNP and crowding of mCy on the GNP surface, LSP 
and sPEG were mixed at a molar ratio of 1:9, and the mixture with GNPs in 
water, for 4 hrs at room temperature. For the amount of LSP/sPEG, 60 
molecule/nm2 -GNP surface area (excess by -15 times) was used; 
(4) The purification of GNP-sPEGILSP, preparation of mCy-BLK, the conjugation of 
mCy-BLK to GNP-sPEGILSP, and the purification and quantification of the final 
product were done by the same way as described in section (b-ii). 
(b-iv) Conjugation of rDSP to GNP and the conjugation of mCy to GNP-rDSP 
rDSP and sPEG were mixed at 1:9 and diluted in ethanol at the same volume of 
the GNP solution to be added; the rest of the steps were the same as steps (2-8) in section 
(b-ii). 
D. CELL STUDIES 
D-l. MATERIALS 
The human breast cancer cell lines, MDA-MB-231 and MCF-7, were purchased 
from American Type Culture Collection (Manassas, VA). Dulbecco's Modified Eagle 
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Medium (DMEM), Penicillin and Streptomycin were purchased through Invitrogen 
(Carlsbad. CA). 
Enzyme-linked immunosorbent assay (ELISA) kit for uPA was purchased from 
Innovative Research (Novi, MI). 
D-2. INSTRUMENTS 
For the cell studies performed in the Achilefu group, the cells were plated on Lab-
Tek slides (BD Biosciences, Franklin Lakes, NJ). The fluorescence of media was 
measured in a Pearl Imager (LI-COR, Lincoln, NE). Fluorescence of cells was visualized 
with an Olympus FVlOOO confocal microscope (Olympus America Inc.; Center Valley, 
PA) using a 20X water immersion objective, and fluorescence intensity was quantified 
with a built-in photon counter. Before any GNP product is applied on the cell culture they 
were sonicated using a sonicator (Sonic Dismembrator; Fisher Science, Chicago, IL) to 
avoid any aggregation. 
For the ELISA of uPA, to mix the reagents in a 96-well plate, the Titer Plate 
Shaker was used (Millipore; Billerica, MA). The fluorescence was measured using a 
Spectra Gemini XPS fluorometer (Molecular Devices Corp.; Sunnyvale, CA) in the 96-
well Uniplate (Whatman; Florham Park, NJ). 
D-3. METHODS 
(a) Quantification of uP A in cell media by ELISA 
MDA-MB-231 and MCF-7 cells were plated at the density of 2500 cells/well (+/-
1 % error in pi petting) in serum-free DMEM Media (150 jlLlwell), in a 96-well plate in 
the Bates laboratory. For MCF-7 cells, 0.01 % Insulin was added. 
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The plate was incubated in CO2 incubator at 37°C. After 8 or 32 hrs of 
incubation, 600 flL of the media sample was collected from both cell lines and frozen at -
70°C immediately. The frozen media was thawed prior to the assay. To remove cells in 
the media, the samples were centrifuged at 13 ,000 rmp for 10 min and the supernatants 
were collected. The ELISA was performed as described below: 
(I) uPA standards of0.1~50 ng/ml was prepared in dilution buffer with BSA; 
(2) The 96-well plate (8x12 removable strips) provided in the ELISA kit had already 
been coated with capture antibody, and blocked and dried. 100 flL of the standard 
and unknown samples were then added to each well, in duplicates, and the plate 
was shaken at 300 rpm for 30 min; 
(3) Blocking buffer (3% BSA in TBS buffer) was used to dissolve primary antibody. 
100 flL of the primary antibody solution was added to each well and the plate was 
shaken at 300 rpm for 30 min; 
(4) The wells were washed with 300 flL washing buffer 3 times and removed. 
Remaining washing buffer was removed by gently tapping plate on paper towel; 
(5) 2 flL secondary antibody was diluted in 10 mL blocking buffer, and 100 flL was 
added to each well. The plate was shaken at 300 rpm for 30 mins and washed with 
washing buffer 3 times; 
(6) 100 flL substrate was added to each well and the plate was shaken for 10 mins. 
The reaction was then stopped by adding 50 flL of IN H2S04 stop solution to each 
well; 
(7) The absorbance at 450 nm was immediately read by Spectra Gemini XPS 
fluorometer. The amount of uPA was quantified. 
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(b) Cell studies with GNP-SSP-Cy 
Cell study with GNP-SSP-Cy was performed at the Achilefu laboratory, 
Washington University, St. Louis, MO. MDA-MB-231 and MCF-7 cells were plated on 
Lab-Tek slides separately, at 3000 cells/well. The plates were incubated in serum-free 
DMEM with 100 units/mL Penicillin and 100 units/mL Streptomycin (for MCF-7 cells 
0.01 % Insulin is added), in C02 incubator at 37°C overnight. The experiment with GNP-
SSP-Cy was done as follows: 
(1) GNP-SSP-Cy was sonicated for 5 min to avoid any aggregation. 
(2) GNP-SSP-Cy was added to the well containing the cells, at the Cypate 
concentration 10 pM, and incubated for 2 hrs. 
(3) After incubation, the media in the well was pi petted out and put in a 96-well black 
plate, and the fluorescence was measured by a Pearl Imager. 
(c) Cell studies with GNP-LSP-mCy 
Cell study with GNP-LSP-Cy was performed at the Achilefu laboratory. The cell 
preparation was done the same as in (b). Then, 
(1) GNP-LSP-mCy was sonicated for 5 min to avoid any aggregation; mCy-BLK or 
GNP-LSP-mCy was added to the wells at the mCy concentration of 340 nM (for 
GNP-LSP-mCy the GNP concentration was 10 nM); 
(2) At 1, 3 and 24 hrs, the slides were removed from the wells and the cells were 
imaged by NIR fluorescence confocal microscope. 
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CHAPTER IV 
RESULTS AND DISCUSSIONS 
A. THEORETICAL ANALYSIS OF FLUORESCENCE ALTERATION BY GNP 
As described in the theory section (Chapter II), the fluorescence alteration by 
GNPs is affected by the GNP size, ExlEm wavelengths and intrinsic quantum yield of the 
fluorophore, and the distance between the GNP and the fluorophore (Fig. 1). Once the 
fluorophore is selected, in a practical sense, the wavelengths of the ExlEm light and the 
quantum yield are fixed. The GNP size and the distance between the fluorophore and the 
GNP are, therefore, the two parameters that can be manipulated. In this section, the effect 
of each parameter on the fluorescence alteration was analyzed for the fluorophores with 
various ExlEm wavelengths (490-830 nm) and intrinsic quantum yields (0.012-0.93), 
which are frequently used in biosensinglimaging applications. Table 1 in Chapter III lists 
the fluorophores (FITC, AF532, Cy3, AF647, AF700 and ICG) and their properties. 
The mathematical model we are using is based on the interaction between a single 
fluorophore and a single GNP, with no inter-particle interaction (Chapter II, Part C, 
Theory). The system is symmetric in the azimuthal axis (dE / dfjJ = 0) and the light is 
applied in the z direction (e = 0). In our study, the following additional assumptions were 
made: 
(1) The fluorophore is placed at e = 0 (along the z axis). 
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(2) For each fluorophore, the excitation and emission are only at their peak wavelength 
values. 
(3) The fluorophore and GNP are placed in water. 
1. Excitation Rate and System Parameters 
(a) GNP size and incident light wavelength 
The GNP size for in vivo application is desired to be in the range of 10-100 nm, 
because this range provides a long circulation time in blood and an effective cell-uptake 
rate [Davis, 2008]. The size includes the thickness of particle surface modification, such 
as coating of polymers and/or other biomolecules conjugated on the GNP surface. The 
core GNP size should be, therefore, smaller than the entire particle size. Based on these 
conditions, the maximum GNP core size studied was 50 nm. For the distance between a 
fluorophore and a GNP (i.e., the spacer length), a range of 0-10 nm was chosen because 
this range provides a plasmon field strength sufficient for affecting the electron status of 
the fluorophore. It is also a range for a linear bio-spacer to maintain its length reasonably 
well. When a fluorophore is selected, the incident light wavelength to be used becomes 
the excitation peak wavelength of the fluorophore. Figure 4 shows the enhancement of 
the excitation decay rate (excitation rate) by a bare GNP of sizes 10, 30 and 50 nm for the 
selected fluorophores at their respective excitation wavelengths, with the distance from 
the GNP surface. 
For all three GNP sizes, on the GNP surface the excitation rates of a fluorophore 
are the same and they are the highest. The rates decrease rapidly with the distance and for 
smaller GNPs, the decrease is faster. Therefore, at the same distance from the GNP, the 
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Figure 4. The enhancement in the 
excitation decay rates of fluorophores 
by their respective Ex wavelengths, 
with respect to the distance from the 
surface of a (a) 10 nm (b) 30 nm and 
(c) 50 nm GNP 
In terms of the fluorophores (i.e., the wavelength of the incident light), AF532 
(Ex 530 nm) shows the highest enhancement (36 times on the surface). Its wavelength is 
slightly red-shifted from the plasmon resonance peak of GNP (520 nm). Hearting's 
analysis [2007] studied that, in a medium with a relative dielectric permittivity greater 
than 1 (The dielectric permittivity in our system is 1.76), the highest enhancement occurs 
at a wavelength slightly red-shifted from the resonance peak. The level for Cy3 (Ex 550 
nm) is only slightly lower. AF700 (Ex 702 nm) and ICG (Ex 780 nm) show lower 
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enhancement (12 times on the surface). The lowest enhancement is for FITC, whose 
excitation peak is at 494 nm, shorter than the GNP resonance wavelength. 
(b) Effect of coating material on GNP 
The plasmon field distribution is also affected by the materials coated on the GNP 
surface. For biomedical applications, GNPs are usually coated with a biocompatible and 
hydrophilic polymer to stabilize GNPs in water-based biological media. The coating also 
prevents protein adsorption on the GNPs. One of the most commonly used polymers is 
PEG. Figure 5 illustrates the plasmon field strength distributions, on and around a 10 nm 
GNP coated with PEG at a thickness of 1, 2 and 3 nm, when the incident light at 780 nm 
is applied. 780 nm is the excitation wavelength peak of ICG , and it is used as an example 
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Figure 5. Plasmon field distributions computed on/around a 10 nm GNP 
coated with PEG, at a thickness of 0, 1, 2, or 3 nm, when the incident light 
at 780 nm is applied. 
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For all three cases, the field strength inside the PEG layer is approximately 15% 
lower than that without the layer (Fig. 5). Therefore if the fluorophore is to be placed 
inside the polymer, then the reduction of the field strength should be considered. 
Immediately outside the layer, the field strength is slightly higher than that without the 
layer. As the distance increase, the strength becomes very close to the one without it. It 
should be noted that this trend is for the coating with dielectric materials. If the coating 
material is metal, the plasmon field may be even enhanced instead of being reduced. 
2. Quantum Yield Affected by Various Parameters 
The change in the quantum yield of a fluorophore by a GNP is the combined 
effect of the plasmon field strength on the radiative decay rate (y,) and the absorption 
( Yah,) of emitted fluorescence by GNPs, and the intrinsic quantum yield of the 
fluorophore, as shown in Eq. 15. 
(a) Radiative decay rate 
Since the radiative decay (y)y;') for the spherical particles may be assumed to be 
the same as Yex)r::" , it is higher for the bigger GNP and is the highest for the 
fluorophores with Ex wavelength slightly red-shifted from the GNP resonance peak. 
(b) Absorption 
The energy of the fluorophore absorbed by the GNP (Yabs) is determined mainly 
by the Em wavelength of a fluorophore. Because the energy is absorbed by the GNPs, it 
is usually the highest at the resonance peak wavelength of GNPs. Figure 6 shows the 
absorption rates by a 30 nm GNP for the fluorophores with respect to the distance. The y-
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axis values are presented in a logarithmic scale due to the wide range of the number 
within the distance. For all fluorophores, on the GNP surface the absorption is extremely 
high (107-108) , and it decreases rapidly with the distance. FITC (Em 521 nm) shows the 
highest absorption (~ 1 08) , and remains very high over the distance studied. For the 
fluorophores with emission wavelength away from the resonance peak, the absorption 
rates are lower than that of FITC. For AF647, AF700 and ICG, the absorptions are the 
lowest. 
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Figure 6. Absorption rate (Yobs / Y; ) of various fluorophores by a 30 nm 
GNP, with respect to the distance from the GNP surface 
(c) Intrinsic quantum yield 
The effect of the intrinsic quantum yield (qO) on the fluorescence may be 
understood better when we write Eq. 3 in the following format: 
q Yr /r; 
qO = qO (y,/y~ +Yabj y; -1)+1 (21) 
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For the fluorophore with high intrinsic quantum yield (~1), q/qO is mainly 
determined by the value of1/(1+YabslYr)' For a fluorophore with very low qO (~0.01) 
such as ICG, the value is larger. It also means that the fluorescence of those fluorophores 
have more tendency to be enhanced. 
Table 3 summarizes values of the first and the second term of the denominator of 
Eq. 21 at 0.1 nm (close), 5 nm (middle) and 10 nm (far) from a 30 nm GNP surface and, 
the third term for the fluorophores. 
Table 3. Normalized radiative decay rate and absorption rate at 0.1, 5 and 
10 nm from a 30 nm GNP surface, and (l_qO)/qO of the fluorophores. 
0.1 om from GNP 5 om from GNP 10 om from GNP 
surface surface surface () 
Fluorophores 
; 0 ! 0 j () ; .. I' /1''' ! 0 (1- q )/q Yr! Yr Yall . ! Yr Yr/ Yr Yah,! y, Ya"';Y r r; r 
FITC 10.1 9.0x106 3.4 543.6 1.9 72.1 0.1 
AF532 32.4 4. 1x106 9.2 244.5 3.9 32.4 0.6 
Cy3 31.6 3.0x106 9.4 180.0 4.1 23.9 5.7 
AF647 15.4 0.66x106 5.4 40.0 2.8 5.3 2 
AF700 13.2 0.54x106 4.8 32.7 2.6 4.3 3 
ICG 11.6 0.55x106 4.4 33.0 2.4 4.4 82.3 
() 
When these three terms are compared, near the surface of the GNP (0.1 nm), the 
f 0 
absorption term Yah.,/ Yr dominates for all the fluorophores. As the distance from the GNP 
; 0 ; 0 ,: a 
increases, both Yr I Yr and I' ab.\! Y r decrease, while Yah.,! Y r decreases much faster. At 5 nm 
from the GNP surface, the Yah) 1':' values for the fluorophores with the emission 
wavelengths close to the GNP resonance peak (FITC, AF532, and Cy3) are still much 
higher than 1''/1';' or (l-q")lq". Therefore, the fluorescence tends to be still quenched. 
For the fluorophores whose Em peaks are away from the GNP resonance wavelength 
58 
(AF647, AF700, and ICG), at 5 run, their Yab)Y~ values decrease to the magnitude 
comparable to Y'/ Y; and (l - qO) I qfl , and their quenching effect dominates no longer. At 
10 run, Y'/Y; decreases up to 1 /3~ 112 of the value at 5 run away, while Yabs/r; decreases 
to ~ 1/8 of its value at 5 run. 
Figure 7a illustrates the quantum yield (q/qO) for the fluorophores near a 30 run 
GNP. ICG is discussed separately (Fig. 7b) because it has an unusually low quantum 
yield (0.012). For all fluorophore, the q/qO values are the lowest at the GNP surface and 
increase with the distance. For FITC, AF532 and Cy3, the values are extremely low even 
at 10 run away from GNP surface due to their large Yabsiy; values. AF700 has greater 
q/qO values than other fluorophores because of its smaller YObJy; and qO values. When it 
is 10 run away from the GNP surface q/qO becomes greater than 1. 
q/qO 
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Figure 7. Theoretically computed quantum yield of (a) various 
fluorophores (b) ICG with respect to the distance from a 30 run GNP 
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For ICG (Fig. 7b), the resulting quantum yield with respect to the distance from 
the GNP shows a unique profile. At the distance less than 1 run, the q/qO is very low. It 
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becomes greater than 1 when the distance is greater than 2 nm. It reaches the greatest (3.4 
times) at 4.2 nm, and then slowly goes down toward 1. Therefore within the distance of 5 
nm, the q/qO value changes from the minimum (on the surface) to the maximum (at 4.2 
nm). 
3. Resulting Fluorescence Output 
The fluorescence output affected by a GNP is the combination of the 
enhancement in excitation decay rate and the change in quantum yield (Eq. 9). Figure 8 
shows the fluorescence output of the fluorophores, by a (a) 10 nm, (b) 30 nm, and (c) 50 
nm GNP. Among the fluorophores studied, ICG shows a unique response to the plasmon 
field generated by the GNP due to its NIR Ex/Em wavelengths and extremely low 
intrinsic quantum yield. Therefore, the fluorescence output for ICG will be analyzed 
separately. For all fluorophores, strong quenching occurs at the GNP surface. FITC 
shows almost complete quenching (>99%) throughout the distance studied, for all three 
GNP sizes. It is mainly because its emission wavelength (521 nm) is close to the plasmon 
resonance peak of GNP and the energy absorption by GNP is very high. FITC is, 
therefore, a good candidate for the fluorescence quenching, but not for the enhancement. 
With a 10 nm GNP (Fig. 8a), for all fluorophores, the fluorescence is quenched 
within 10 nm from the GNP surface. Therefore, 10 nm GNP may be a good candidate for 
conditional fluorescing, such as molecular beacon, for these fluorophores. 
As the GNP size increases, the level of fluorescence becomes higher for all 
fluorophores. For a 30 nm GNP, the fluorescence levels of Cy3, AF647 and AF700 are 
quenched within 2 nm from the GNP surface, and start to get enhanced when the distance 
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is greater than 3 nm. When the distance becomes approximately 9 nm, the enhancement 
becomes 2.5-4 times and afterwards, slowly decreases. 
For a 50 nm GNP, the distance for fluorescence quenching is even shorter and the 
fluorescence enhancement is greater and starts at a shorter distance than for the 30 nm 
GNP. The enhancement for Cy3 , AF647 and AF700 is up to 5-10 times. Even the 
fluorescence of AF532 gets enhanced at a distance of 4.5 nm. The distance for the 
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Figure 8. Theoretical estimation of 
fluorescence output of various 
fluorophores affected by a (a) 10 (b) 30 
and (c) 50 nm GNP 
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The theoretical study results for fluorescence manipulation using GNPs may be 
summarized as follows: 
For fluorescence quenching: 
(1) The fluorophores with the Em wavelength near the GNP plasmon resonance peak 
are good candidates. 
(2) On the GNP surface, the fluorescence of fluorophores is always quenched. 
(3) For the fluorophores with Em wavelengths significantly longer than the GNP 
resonance peak, e.g., far-red or NIR fluorophores, the distance between the GNP 
and the fluorophore needs to be shorter to achieve the same level of quenching. 
(4) Bigger GNPs require shorter distance from the fluorophore to quench the 
fluorescence. 
For fluorescence enhancement: 
(l) Only the fluorophores with Ex/Em wavelengths longer than the resonance peak 
wavelength of GNP, may be effectively used for fluorescence enhancement. 
(2) The GNP size needs to be sufficiently large to generate a plasmon field strong 
enough to enhance fluorescence. In general, bigger GNPs provide greater 
fluorescence enhancement. 
(3) The fluorophores with a lower quantum yield have more potential for the 
fluorescence enhancement. 
(4) To obtain the maximal fluorescence enhancement, the distance between a 
fluorophore and a GNP needs to be accurately selected. 
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4. leG Fluorescence Alteration by GNPs 
The fluorescence of ICG altered by a GNP was studied more in details here 
because ICG is the basis of Cypate, the fluorophore used in our experimental studies, and 
because it has Ex/Em wavelength in NIR and a very low quantum yield (Table 1). 
Figure 9 shows the enhancement of the excitation decay rate by ICG excitation 
wavelength (780 nm) by GNPs at the size range of our interest, with the distance from the 
GNP surface. As for other fluorophores, larger GNPs provide greater enhancement, 
although the values are lower (~ 12) than those for the fluorophores close to the GNP 
resonance wavelengths (~36) . 
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Figure 9. The enhancement in the excitation decay rates of ICG (Ex 
wavelength 780 nm) by GNPs at various sizes. 
For the quantum yield of ICG, the effects of the absorption rate and the intrinsic 
quantum yield were analyzed in detail because of the uniqueness of ICG in these two 
aspects. The absorption rate (Yab) Y~) oflCG by GNP with distance from GNP is shown 
in Figure 10. Previously the values for other fluorophores were presented in logarithmic 
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scale (Fig. 6), but to provide a better view of the values for leG in the distance and to 
compared it to the excitation rate, here, the values are presented in a linear scale. The 
absorption rate on the GNP surface is extremely high (~ 1 06) , but the rate decreases very 
fast with distance. Fig. lOb shows the magnified section of the absorption rate in the 
distance range of 2-10 nm. At 2 nm, it already decreases to 470. The absorption still 
decreases fast after 2 nm. At 5 nm, the absorption decrease to 33 , and at 10 nm, 4.4, a 
similar magnitude as the radiative decay rate and smaller than the intrinsic quantum yield 







I 500 r----------------, 
J (b) 
II 400 
S.OE+06 I I 
4.SE+06 I 300 I 













Distance from the GNP surface (nm) 
5.0E+05 
O.OE+OO 
" .-------------- I,," 
I I. 
----------------0 2 4 6 8 10 
Distance from the GNP surface (nm) 
Figure 10. (a) Absorption rate (YlIbS/Y;) of leG by a 30 nm GNP, with 
respect to the distance from the GNP surface (b) magnified view of the 
section in the rectangle in (a) 
Figure 11 shows the quantum yield change of leG near the GNP at various sizes, 
which is the combined effect of the in radiative decay rate, absorption rate and intrinsic 
quantum yield. Bigger GNPs provide greater quantum yield. When the distance is less 
thanl nm, the quantum yield is highly reduced due to the strong absorption shown in Fig. 
lOa. As the distance increase, the absorption decreases much faster than the radiative 
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Figure 11. Theoretically computed quantum yield change of leG (Ex/Em 
780/830 nm) with the distance from the GNP at various sizes 
The fluorescence output is the product of the excitation rate and the quantum 
yield (Eq. 9; Figs 9 and 10). Figure 12 shows the fluorescence change of leG by a GNP 
of the size 5~50 nm. With 5 nm GNP, the leG fluorescence is quenched within 4 nm. At 
the distance longer than 4 nm, the level is similar to that without the GNP. Therefore, 5 
nm GNP may be effectively used as a quencher for leG. For the 10 nm GNP, the 
fluorescence is quenched only within 1.3 nm from the GNP, and gets enhanced thereafter. 
It reaches the highest enhancement (2.4 times) at 3.4 nm. As the GNP size increase, the 
distance for quenching becomes even shorter, and the maximal fluorescence 
enhancement becomes higher. In general, the distance for the maximal enhancement is 
shorter than those for other fluorophores. For bigger GNPs, the distance for maximal 
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enhancement is longer, as for other fluorophores. For the 15, 30 and 50 nm GNPs, the 
maximal enhancements are 5, 14, and 26 times, at the distance of 3.4, 3.9 and 4.4 nm, 
respectively. The enhancement values are much greater than those for the other 
fluorophores studied, mainly due to its very low intrinsic quantum yield. 
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Figure 12. Theoretically computed fluorescence emission ofICG (ExlEm 
780/830 nm) with the distance from the GNP of various sizes 
As can be seen from Figs. 8-12, the fluorescence alteration of ICG features a 
unique pattern. Both quenching and the maximal enhancement occur within a short (~5 
nm) distance range. This unique property became the basis for our design of the contrast 
agent that conditionally changes fluorescence level from quenching to enhancement at 
presence of a particular enzyme, which is presented in the experimental section of this 
dissertation. 
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B. EXPERIMENTAL STUDY 
ICG fluorescence is predicted to be changed by GNP from complete quenching to 
extensive enhancement, within 5 nm from the GNP surface as shown in the theory 
section (Fig. 12). Utilizing this unique property, a novel optical contrast agent for 
molecular imaging was designed (Fig. 13). As a model system, the contrast agent was 
developed for breast cancer detection. 
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Figure 13. (a) Design of highly cancer specific fluorescing cancer locator. 
The agent normally does not emit fluorescence because the short spacer 
place Cypate very close to the GNP. (b) When the cancer locater binds to 
the cancer cell, it is exposed to the cancer secreting enzyme. The short 
spacer is cleaved by the enzyme from cancer cell and the fluorescence is 
emitted at an enhanced level. 
1. Components of the Contrast Agent 
The components of the contrast agent are: a GNP, the materials for GNP surface 
treatment (sPEG), spacers (SSP and LSP), Cypate and targeting molecules. 
67 
(a) GNP 
In our experimental studies, the GNP core at the sizes of 5, 10 and 15 nm were 
used. It should be noted that the sizes 5, 10 and 15 were the ones claimed by the 
manufacturer. The actual sizes according to our measurements by the light scattering 
analysis and TEM were 3.7,8 and 16.4 nm, respectively. 
(b) GNP surface modification 
The SAM of HS-(CH2)w(CH2CH20)3 (sPEG) was used to stabilize GNPs. The 
HS- group is for reacting to GNP surface. The hydrocarbon chain section (-1.5 run by the 
molecular simulation) of sPEG is straight and hydrophobic for tight packing on the GNP 
surface, and the PEG section (0.9 run by the simulation) is flexible and hydrophilic. The 
length estimation was done by a computer code assuming that the molecule was in an 
extended configuation in vacuum, and, therefore, the actual length may be slightly 
different in the physiological conditions. 
(c) Spacers 
(c-i) Short spacer (SSP) 
A short spacer was used to place Cypate at a distance from the GNP for its 
fluorescence to be quenched. The spacer must contain a motif that can be cleaved by a 
cancer-secreting enzyme. In our model system, the enzyme was urokinase-type 
plasminogen activator (uP A). uP A is expressed in a number of malignant breast cancers. 
The Gly-Gly-Arg amino sequence is a substrate of uPA, and, therefore, our short spacer 
was HS-(CH2)2-Gly-Gly-Arg-Gly-Gly-Gly-NH2 (or -ONH2). The HS- ending is for 
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binding it to the GNP surface and the -NH2 or -ONH2 ending is to link it to Cypate or m-
Cypate. 
(c-ii) Long spacer (LSP) 
The long spacer is to keep the distance between Cypate and the GNP at the length 
producing the maximum fluorescence enhancement. The spacers were designed to have a 
similar structure as the sPEG to allow the LSP forming a well-mixed monolayer with 
sPEG on the GNP surface. They were HS-(CH2)m-PEGn-ONH2. By varying the numbers 
m (12 or 16) and n (4, 6 or 8), the length of the spacer was varied. The -ONH2 ending is 
for m-Cypate conjugation. 
(d) Fluorophore 
Our fluorophore is Cypate, an ICG derivative. ICG does not have any functional 
group to conjugate biomolecules (Figure 14a). Achilefu, et al. [2000; 2002] slightly 
modified the structure of ICG and created Cypate with two carboxylic groups (Figure 
14b), which can then react to amine groups of biomolecules by using a coupling agent to 
activate the carboxylic groups. However, there are many biomolecules with carboxylic or 
amine groups. Therefore, we decided to use -CHO/-ONH2 reaction. The Nantz-group, our 
research partner, added adelhyde (-CHO) groups to the carboxylic ends of Cypate to form 
a modified-Cypate (m-Cypate; Figure 14c). The adelhyde group allows the oxime 
coupling with the aminooxy ending (-ONH2), forming stable oxime bound. This reaction 
does not require additional coupling agent and is not interfered by other peptides and 
proteins. 
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If only one of the two -CHO endings of m-Cypate needs to be reacted, blocking 
agent (BLK), (CH3hN+-(CH2)2-0NH2, was used to block one ending. The BLK also 
helps to increase the hydrophilicity of Cypate, preventing from m-Cypate being adsorbed 
to the hydrophobic hydrocarbon chain of the sPEG or LSP. 
Figure 14. Molecular structures of (a) ICG and (b) Cypate (Supplied by 
the Achilefu group) (c) m-Cypate (Modified by the Nantz group) 
(e) Targeting molecule 
Tamoxifen and Herceptin are selected to be the targeting molecules. Tamoxifen is 
a drug currently used to treat estrogen receptor positive (ER+) breast cancer. It works as 
an antagonist that binds to the ER, which is over-expressed in 70% of breast cancer. 
Herceptin is an antibody that binds to Human epidermal growth factor receptor 2 
(HER2), which is over-expressed in 20-30% of early-stage breast cancer. 
This contrast agent is to emit little fluorescence (the fluorescence is to be 
quenched). It is to be preferentially delivered to the cancer site via the targeting molecule 
(Fig. 1 Ob). The the agent is placed in an environment with uP A. When the short spacer is 
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cleaved by uP A, the distance between the Cypate and the GNP is now at the long spacer 
length. The fluorescence changes from a quenched level to an enhanced level, detecting 
the cancer with high specificity and contrast. 
The development steps of this contrast agent were as follows: 
1. Characterization of individual components of the system 
2. Optimization of spacers 
(a) Optimization of the short spacer (conditional fluorescence quenching) 
(b) Optimization of the long spacer (maximal fluorescence enhancement) 
(c) Construction and testing the dual-spacer 
3. Conjugation of targeting molecule 
4. Cell study 
In this dissertation the results from the steps 1, 2, and a part of 4 are presented. 
2. Characterization of the Components 
(a) The effect of the solvent on Cypate fluorescence 
Cypate is hydrophobic due to its aromatic part and long polymethine chain. It has 
a low solubility in water and forms aggregates in water [Licha, et al., 2000]. The intrinsic 
quantum yield (QY) of Cypate in water (0.0028) is lower than that in blood plasma 
(0.012). One way of avoiding the Cypate aggregation in water is by increasing the ionic 
strength in water. Figure 15 shows the fluorescence of Cypate in water, and 10 mM PBS. 
The Cypate fluorescence is extremely low in water. In PBS, the Cypate fluorescence is 
approximately 150 times higher than that in water. The fluorescence in 1 mM PBS is 
similar to that in 10 mM PBS (only 7% less). Colloidal GNPs stabilized with citric/tannic 
acids, without special surface treatment, easily precipitate in the solutions with high ionic 
71 
strength (e.g., 10 mM PBS buffer). Therefore, In the preliminary studies involving 






:::::> 140 u.. 
~ 120 5 
i 100 (.) 
(f) 80 ~ 





Water 1 mM PBS 10mM PBS 
Figure 15. Fluorescence of Cypate in water, 1 and 10 mM PBS buffer 
(Cypate concentration: 30 J..lM) 
(b) Cypate concentration and self-quenching 
Fluorophores quench their own fluorescence when their concentration exceeds a 
certain level (inter-molecular quenching), either by the collision among excited and 
ground-stated fluorophores (dynamic quenching) or by forming the ground-stated 
fluorophore complexes (static quenching) [Ingle and Crouch, 1988; Johansson, et at., 
2002]. To avoid the inter-molecular quenching, we have observed the Cypate 
fluorescence level with respect to the concentration at a range of 5~ 150 !lM (Fig. 16). 
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Figure 16. Fluorescence ofCypate at various Cypate concentrations (in 10 
mM PBS) 
The fluorescence increased with the increase in Cypate concentration up to 30 
flM. At concentrations higher than 30 flM, the fluorescence decreased. Therefore, the 
Cypate concentration less than 30 flM was used for further studies. 
(c) Fluorescence of free Cypate affected by free GNP colloids 
One simple way of changing the average distance between the GNP and the 
Cypate is by varying the concentration of GNPs. The fluorescence of free Cypate affected 
by colloidal GNPs of various concentrations was studied for 5 and 10 nm GNPs at a 
weight (wt) concentration range of 0-60 /lg/ml (molar concentration: for 5 nm GNP, 
0-75 nM, and for 10 nm GNP, 0-8.5 nM) at a Cypate concentration 30 flM, which is the 
maximum concentration without self-quenching (Fig. 17). In this experiment, GNP 
concentration is, therefore, the limiting factor. 
When the GNP concentration is very low « 6 /lg/ml), the GNPs enhanced the 
fluorescence. This phenomenon may be explained by figure 15. For free GNPs and 
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fluorophores, when the fluorophore concentration is fixed, the distance between the GNP 
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Figure 17. Fluorescence of free Cypate with various concentrations of free 
GNP (Cypate concentration for both GNP sizes 30 nM). 
At concentrations greater than 6 Ilg/ml (for 5 nm GNP, 8.3 nM, for 10 nm GNP, 
1.0 nM), the fluorescence was quenched, and the quenching level increased with the 
increase in GNP concentration. At the same wt concentration, 5 nm GNPs showed 
greater quenching than those at 10 nm, probably because the number of 5 nm GNPs is 8 
times greater than that of 10 nm GNP, and the total surface area is about 2 times larger. 
Also, due to its smaller size, 5 nm GNPs would have much greater mobility than 10 nm 
GNPs would, resulting in greater probability for Cypate to be near the GNP. In addition, 
as shown in the theory section, smaller GNPs tend to cause quenching. 
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When the GNP concentration is very low [Fig. 18(b), with one GNP] , the average 
distance between Cypate and GNP is longer, and the fluorescnece is either slightly 
enhanced or unaffected. At a higher GNP concentration [Fig. 18(a), with three GNPs] , 
the distance between GNP and Cypate is shorter and, thus, more Cypate molecules are 
near the GNP surface, resulting in more fluorescence quenching. 
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Figure 18. Schematic diagram for fluorescence of free Cypate affected by 
(a) high and (b) low GNP concentration in solution 
As a preliminary study, this result verified that the GNPs affect Cypate 
fluorescence from quenching to enhancement, depending on the GNP concentration 
(distance between GNP and Cypate). 
3. Optimization of Spacers 
(a) Short spacer 
Figure. 19 is a schematic diagram demonstrating the mechanism of the short 
spacer in the contrast agent of our interest. sPEGs are packed on the GNP surface for 
stabilizing the GNPs. Cypate is conjugated to GNP via the short spacer. The methods for 
conjugating Cypate to GNP via short spacer were: (1) Cypate (Cy) conjugated SSP (Cy-
SSP) was mixed with sPEG at a predetermined ratio and the mixture was reacted with 
GNPs to form a monolayer of two different molecules on the GNP surface, or (2) The 
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SSP with the - ONH2 ending (nSSP) was mixed with sPEG at a predetermined ratio and 
the mixture was reacted with GNPs to produce GNP-nSSP. Then the m-Cypate reacted 
with BLK was reacted to the GNP-nSSP . 
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Figure 19. A schematic diagram of the uPA triggered fluorescence 
contrast agent, Cypate conjugated GNP via a short spacer: (a) normally 
emits little fluorescence (b) in the presence of uP A enzyme, the spacer is 
cleaved and the fluorescencing ability of the agent is restored. 
For our system, SInce the short spacer and the fluorophore were already 
determined, the only parameter that could be varied was the GNP size. Theoretical study 
results suggested that smaller GNPs provided more effective quenching with the same 
distance between the GNP and the fluorophores. We, therefore, decided to first test 
relatively smaller GNPs, i.e. 3.7, 8.9 and 16.4 nm GNPs. 
(a-i) Characterization of GNP-SSP-Cy 
The GNP-SSP-Cy produced was characterized by UV -Visible spectroscopy to 
confirm the presence of both GNP and Cypate and to study their optical properties. 
Figure 20(a) shows the absorption spectra of GNP, SSP-Cy and GNP-SSP-Cy when 8.0 
nm GNPs were used. GNPs and SSP-Cy show their signature absorption peaks at 520 and 
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780 nm, respectively. GNP-SSP-Cy shows the peaks of both GNP and SSP-Cy. The 
peaks were slightly red-shifted, probably due to the changes in the refractive index of the 
GNPs after the polymer conjugation. 
GNP-SSP-Cys were spread on TEM grid as a monolayer and dried under vacuum. 
TEM was performed to visualize the GNP core and potentially the coating [Fig. 20(b)]. 
The image shows a uniform GNP core size of 8.0 nm. The sPEG coating is not visible 
because usually polymers do not respond to the electron beams well. Since TEM requires 
the sample to be dried and is performed in a high-vacuum, the image may not show the 
dispersion property of GNP-SSP-Cy in solution. Nonetheless, the particles are separated 
from each other at a constant distance, which is speculated to be the thickness of two, dry 
sPEG layers. Dynamic light scattering particle size analyzer was not used for this GNP 
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Figure 20. (a) Absorption spectra of GNP, SSP-Cy and GNP-SSP-Cy, and 
(b) TEM image ofGNP-SSP-Cy [GNP, 8.0 nm] 
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(a-ii) Effect of the GNP size on fluorescence quenching 
The fluorescence levels for the GNP-SSP-Cy products with GNP core size of 3.7, 
8.0, 16.4 run, were observed and compared with that of SSP-Cy alone (Fig. 21). The 
Cypate concentration in all GNP-SSP-Cy samples was adjusted to 10 IlM, using the 
absoption at 780 run. At this Cypate concentration, the GNP concentration determined by 
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Figure 21. Relative fluorescence of the GNP-SSP-Cy with 
the core GNP size of 3.7, 8.0 and 16.4 run at 10 IlM 
Cypate concentration in PBS buffer 
For 3.7 and 8.0 run GNPs, the fluorescence was quenched by 95% and 94%, 
respectively. For 16.4 run GNP, however, the fluorescence was enhanced by 120%. 
Therefore, 3.7 and 8.0 run GNPs were used in our further studies. 
Figure 22 shows the theoretical estimation of the fluorescence of Cypate placed 
near a GNP of 3.7, 8.0 and 16.4 run. It shows that to obtain the fluorescence alteration 
level shown in Fig. 21 , the spacer lengths should be 0.4, 0.3 and 1.5 run, for 3.7, 8.9 and 
16.4 run GNPs, respectively. They are much shorter than the SSP length that we 
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estimated by the simulation, although the trend that bigger GNP results III higher 
fluorescence qualitatively agrees with the experimental results. 
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Figure 22. Theoretical estimation of fluorescence emission 
with the distance from the GNP surface for the GNPs sizes 
at 3.7, 8.0, and 16.4 nm for ICG (Ex/Em 780/830 nm) 
The discrepancy between the experimental result and theoretical prediction may 
be because: 
(1) The length estimation for SSP was done by a molecular simulation assumes SSP 
to be extended configuration in vacuum, while in the actual system they were in 
a water based buffer and may not be linear. 
(2) The theoretical result shown in Fig. 22 was for bare GNPs. In our experimental 
system, the GNPs were coated with sPEG, and Cypate is outside the sPEG layer, 
where the plasmon field may be slightly stronger than the one without sPEG 
coating (See Fig. 7). 
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(3) The theoretical model is based on a system with a single fluorophore and a single 
GNP with no inter-particle or inter-fluorophore interference. In the experimental 
study, multiple fluorophores were conjugated to a single GNP, and multiple 
GNP-SSP-Cys were dispersed in the solution. There may be interaction among 
the particles and fluorophore molecules, e.g., self-quenching may occur among 
the Cys on the GNP and the fluorescence of GNP-SSP-Cy may be affected by the 
GNP of another GNP-SSP-Cy nearby. 
(4) The theoretical analysis here was done only in one direction (8 =0), i.e., the 
effect of other directions were not considered, while, in the experimental system, 
Cypate is conjugated all around the GNPs. The field strength varies with S, thus 
the fluorescence alteration value is also different for different S. 
The theoretical and experimental results, however, qualitatively agree in the sense 
that, at the same distance from the GNP surface, smaller particles provide less 
fluorescence. 
(a-iii) Conditional fluorescence restoration 
Our model system is to fluoresce only in the presence of uPA. The GNP-SSP-Cy 
products showing the fluorescence quenching (i.e., with 3.7 and 8.0 nm GNP cores) were 
tested with a sufficient amount of uP A (1030 units/mI), and their fluorescence changes 
were observed. Figure 23 shows the fluorescence levels of the GNP-SSP-Cy before and 5 
minutes after uPA was applied. The fluorescence of 3.7 and 8.0 nm GNP-SSP-Cy was 
restored up to 21 and 43%, respectively. 
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Figure 23. The relative fluorescence levels of GNP-SSP-Cy with 3.7 
(GNP concentration 31 nM) and 8.0 nm (GNP concentration 7 nM) GNPs 
at 10 !!M Cypate in PBS buffer, before and after adding uP A. Reaction 
time: 5 min; ExlEm: 780/830 nm 
Ideally, when uPA reacts with the GNP-SSP-Cy, the fluorescence is to be 
completely (100%) restored. The possible reasons for this partial fluorecence restoration 
were: (i) the Cypate molecules freed from the GNPs would be still placed very close to 
GNPs because of the high GNP concentration and the fluorescence niight be still 
quenched; (ii) SSP and sPEG molecules might be packed tightly on the GNP surface and 
uPA would not have easy access to the uPA-substrate site in the SSP. This may be 
resolved by replacing sPEG with shorter PEG molecules; and (iii) the released Cypate 
molecules might have been adsorbed at the hydrophobic site of sPEG. 
We have first tested the hypothesis (i). The relative fluorescence of 10 nm GNP-
nSSP-mCy before and after adding uPA was observed at various GNP concentrations, 
while the mCy/GNP ratio is fixed (performed by Dr. Robert Lupitskyy; Fig. 24). The 
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GNP concentrations tested (2.5 , 5, and 10 nM) were in the range of the concentration 
used in our previous studies [Fig. 17 (7 nM)]. 
The GNP-nSSP-mCy as it is, showed very little fluorescence «5% of the 
control). When uP A was applied to the sample, the fluorescence restoration for the GNP 
concentration of2.5, 5, and 10 nM were 71 , 42 and 12%, respectively, indicating that the 
restoration rate is highly affected by the GNP concentration in the solution. We expect 
that at a lower GNP concentration the fluorescence will be fully restored. We were, 
however, not able to further lower GNP concentration, because at the GNP concentration 
at 2.5 nM, the mCy concentration reaches the lower limit (~40 nM) for a reliable 
fluorescence measurement. 
This result suggested that the higher GNP concentration [i.e. (i) described above] 
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Figure 24. Fluorescence of GNP-nSSP-mCy with 8.0 nm GNP at various 
GNP concentrations, before and after adding uP A, Reaction time: 5 min; 
ExlEm: 780/830 nm 
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(b) Long Spacer 
The main role of the long spacer (LSP) is to maximize the Cypate fluorescence for 
a GNP size selected. The theoretical results (Fig. 12) shows that the enhancement level is 
determined by the distance and the GNP size. For the spacers, the LSPs previously 
described (B-l. components of the contrast agent, b-ii) were tested for the Cypate 
fluorescence enhancement. For the GNP size, bigger GNPs provide a greater maximum 
enhancement and require a shorter distance for fluorescence quenching. For our system, 
however, the length of the short spacer was already fixed, and therefore, to maintain a 
satisfactory level of quenching the upper limit of the GNP size to be used was already 
determined. The GNP size to be tested for our system was therefore decided to be less 
than 20 nm (3.7,8.0 and 16.4 nm). 
As previously described, sPEG is used for GNP surface modification and also for 
adjusting the spacing between the two adjunct fluorophores on the GNP surface. After 
testing several LSP-to-sPEG ratios, 1:9 was found to be working well without causing 
aggregation. The purified GNP-LSP was then reacted with m-Cypate (with BLK) to 
produce GNP-LSP-mCy. 
(b-i) Characterization of GNP-LSP 
According to our theoretical study results for the GNPs at a size range of 5-50 nm 
that enhance the ICG fluorescence, the distance between a GNP and ICG is in a range of 
2-5 nm. Table 4 listed the spacers used in this study and their lengths estimated by a 
molecular simulation. Again, the mathematical model used to compute the length of the 
spacers assumes that the molecule is straight and in vacuum. 
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In an attempt to verifY the spacer conjugation and also to know the actual length 
of the spacer, the GNPs conjugated with the SPs and sPEG were characterized by the 
dynamic light scattering (DLS) size analysis and TEM. 
Table 5 shows the particle size measured by DLS, before and after the 
conjugation. 
Table 5. Size ofnanoparticles, before and after conjugating sPEG and 
sPEGI LSP, measured by light scattering particle size analyzer 
Sample 5nmGNP 10nmGNP 15 nm GNP 
Uncoated GNP 3.7 ± 0.9 8.0 ± 1.5 16.4 ± 0.90 
GNP-sPEG 8.0 ± 1.6 10.2 ± 0.9 17.5 ± 1.3 
GNP-sPEG/C 12PEG4 8.3 ± 1.1 11.2 ± 1.2 17.9±1.2 
GNP-sPEG/C12PEG6 11.2 ± 2.3 10.5 ± 1.7 18.1 ± 3.1 
GNP-sPEG/C 12PEG8 10.1 ± 1.6 11.5 ± 1.9 17.0±3.8 
The diameter of the particles increased by 1.5-7.5 nm after coating. In general, the 
increase in diameter measured by DLS appeared to be much less than those theoretically 
estimated (6.4-9.2 nm, double of the length of the SPs), indicating that the actual length 
of the sPEG of spacers may be shorter than the estimation. In addition, the difference in 
the size between the GNP-sPEG and the GNP-sPEG/SPs was minimal, possibly because 
the majority molecules on GNP surface are sPEG. For bigger GNPs, the increase was less 
than the ones for smaller particles. DLS measures the hydrodynamic diameter of particles 
based on the diffusion of particles in the fluid. With the same polymer coating thickness, 
84 
the movement of a particle with a bigger heavy (gold) core may be less affected by the 
light coating, results in less change in the particle size. 
The particles were also imaged by TEM. Because TEM does not usually respond 
to organic polymer well, therefore, we put an extra effort to spread diluted GNP products 
on the TEM grid so that the particle solution formed a thin particle monolayer. The 
spacing between two adjacent particles was expected to be the thickness of two layers of 
spacers on GNP. Figure 25 shows the 8.0 nm GNPs conjugated with (a) sPEG and (b) 
sPEG and C12PEG6 spacer. The distance between two adjacent particles were measured 
at least 50 different arbitrarily selected locations and the mean distance was 1.2±0.1 nm 
for all samples. Again, no notable difference in layer thickness was observed among the 
GNPs coated with various spacers, probably because the polymer layer thickness in the 
TEM was represented mainly for sPEG. It should also be noted that the samples prepared 
for the TEM were dried under vacuum, and therefore, the actual thickness of the coating 
layer in aqueous solution may not be the same as the one shown in TEM images. A 
technique that can be used for this type of analysis is urgently needed for bio-nano 
research. 
(a) (b) 
Figure 25. TEM image of8.0 nm GNPs coated with (a) sPEG only and (b) 
sPEG and C 12PEG6 
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(b-iii) Spectroscopic analysis of GNP-LSP-mCy 
GNP-LSP-mCy was characterized by UV -Vis spectrometry to confirm the Cypate 
conjugation. Figure 26 shows the absorption spectra of GNP, GNP-sPEG, GNP-
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Figure 26. Absorption spectra of 8.0 run GNP, GNP coated with sPEG 
alone, with sPEG and C12PEG6, GNP-LSP-mCy, and mCy 
The absorption spectrum of GNP-sPEG is very similar to GNP except that the 
absorption peak was slightly red-shifted, caused by the changes in refractive index by the 
polymer coating. When the GNP is coated by both sPEG and LSP (C12PEG6), the peak 
showed a slightly greater red-shift. After reacting mCy onto the GNP via the LSP, the 
spectra showed both GNP and mCy absorption peaks. The concentrations of GNP and 
mCy were estimated by the absorption at their respective signature wavelengths. 
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(b-iv) Application of blocking agent for m-Cypate 
For binding Cypate to GNPs via the LSPs, initially mCy was reacted to GNP-LSP, 
as it was, without using BLK. After the product was purchased and tested for the 
fluorescence emission, strong fluorescence quenching was observed for all the LSPs. We 
speculated that the quenching might be caused by one or both of the following potential 
reasons (Fig. 27a): (i) mCy has two -CHO groups that can react to the -ONH2 group of 
the spacers. Therefore, it may react to two LSPs on the same GNP or on different GNPs, 
and the later may place GNP very close to mCy, or (ii) Cypate is hydrophobic and it may 
be adsorbed to the hydrophobic -(CH2)m- part of sPEG and LSPs (Fig. 27a), before or 
after it binds to LSPs. Thus the distance between the mCy and GNP surface becomes 
short and it leads to fluorescence quenching. 
To resolve these issues, (CH3)3N+-(CH2h-ONH2 was used as the blocking agent. 
It was mixed with mCy at a 1: 1 molar ratio, assuming that it blocks one of the two CHO 
groups of mCy so that each mCy reacts to only one LSP (Fig. 27b). Since BLK is 
hydrophilic, it is expected to increase the hydrophicility of mCy and thus helps avoid 
adsorption of mCy to the hydrophobic inner layer on GNP surface. With the use of BLK, 
the quenching problem disappeared and fluorescence enhancement with respect to spacer 
length and GNP size was observed instead of quenching. 
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Figure 27. Schematic diagram of the function of blocking agent. (a) 
Without BLK (i) m-Cypate reacts to more than one LSPs and is placed 
very close to GNPs or (ii) m-Cypate is adsorbed to the hydrophobic 
section of sPEG and LSP. (b) One of the two -CHO group on m-Cypate is 
blocked therefore each LSP reacts to one m-Cypate, and m-Cypate is not 
adsorbed to the hydrocarbon chain close to the GNP surface. 
(b-v) Effect of LSP length on fluorescence enhancement 
Figure 28 shows the relative fluorescence of the GNP-LSP-mCy at various LSP 
lengths [HS-(CH2)m-PEGn-ONH2, m=12 or 16, n=4, 6, or 8; 3.2-4.6 nm], when 8 nm 
GNP was used. 
The shortest spacer, C12PEG4 (simulated length estimation, 3.2 nm), resulted in a 
fluorescence quenching by 14%. For C16PEG4 (3.7 nm), the fluorescence was enhanced 
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by 36%. The fluorescence of GNPs with C12PEG6 (3.7 nm) and C16PEG6 (3.9 nm) 
showed the enhancement of two times. For the spacers longer (C12PEG8, 4.6 nm) than 
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Figure 28. Relative fluorescence ofmCy conjugated to 8.0 nm GNP via 
spacers with various lengths 
When the results of theory and experiment were compared (Fig. 29), the level of 
the maximum enhancement was similar (- 2 times). However, the distance showing the 
maximum in the theoretical result was slightly shorter than the corresponding 
experimental spacer lengths. If the theoretical values were shifted by 1 nm (dotted line), 
they fit to the experimental values well except the value for the spacer C12PEG8. The 
reason for this discrepancy may be that the spacer length in the aqueous environment may 
be slightly different from those estimated by the simulation with the assumption that the 
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Figure 29. Relative fluorescence ofmCy-BLK conjugated to 8.0 nm GNP 
via the spacers with various lengths, compared to the theoretically 
estimated fluorescence. 
(b-v) Effect of GNP size on fluorescence enhancement 
Theoretical study results show that, in general, bigger GNPs provide the greater 
fluorescence enhancement. We experimentally tested the changes in the Cypate 
fluorescence caused by three different GNP sizes (3.7, 8.0 and 16.4 nm). For this study, 
the spacers, C12PEG4 (3.2 nm), C12PEG6 (3.9 nm) and C12PEG8 (4.6 nm) were used. 
Figure 30 shows both theoretical and experimental results of fluorescence 
alteration by 3.7, 8, and 16.4 nm GNP. 
When 3.7 nm GNPs were used, the Cypate fluorescence was quenched for all 
spacers. The shortest spacer, C12PEG4 (3.2 nm), resulted in the most quenching (60%) 
as expected, and C12PEG6 (3.9 nm) and C12PEG8 (4.6 nm) showed the quenching of30 
and 40%, respectively. These results indicates that the 3.4 nm GNP may be too small to 
enhance the Cypate fluorescence, but it can be used as an effective quencher, and a 
shorter spacer may be desired for greater quenching. The experimental results 
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qualitatively agreed with the theoretical predication, although the two results fit better 
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Figure 30. Relative fluorescence 
emjamcement of mCy conjugated to 
(a) 3.7 (b) 8.0 and (c) 16.4 run GNPs 
via spacers with various lengths, 
compared to the theoretically 
estimated fluorescence level. 
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Distance (nm) 
For 8.0 run GNP, the result has already been discussed. 
With the 16.4 run GNP, C12PEG4 caused 50% quenching, while C12PEG6 and 
C12PEG8 provided the enhancement of 3.6 and 2.7 times, respectively, greater than that 
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by the 8.0 run GNP (2 times). When it is compared to the theoretical results, the 
magnitudes of fluorescence changes by the spacers C 12PEG4 and C 12PEG6 are similar 
to those by the theoretical results that are shifted by 2 run in the x-axis. However, the one 
with C 12PEG8 was significantly lower than the theoretical value. 
Both theoretical and experimental results confirmed that for fluorescence 
enhancement, GNP size needs to be sufficiently large, and bigger GNPs provide the 
greater maximum enhancement. The results also show that the spacer length needs to be 
carefully selected to obtain the maximal enhancement. When the experimental results 
were compared to the theoretical values, the estimated length of the spacer used in the 
experiment were 1-2 run longer than those of the theory. This phenomenon was observed 
in the short spacer study and previous studies from the Kang group [Kang, et al., 2011; 
Wang, et al., 2011], and the possible causes for the discrepancy have been discussed in 
the short spacer study. Although the exact reasons for this discrepancy were not fully 
understood yet, the difference is not significant. Therefore, the theoretical prediction is 
still very valuable in selecting the proper parameters for developing appropriate contrast 
agents using GNP, which reduces the number of experiments significantly. 
In the process of designing and finalizing our dual spacer an important constraint 
is that the conditions need to satisfy both short and long spacer performance. Although 
16.4 run GNP provides the greatest fluorescence enhancement, it does not quench the 
fluorescence with the short spacer. Therefore, for the dual spacer system, 8.0 nm GNP, 
which provides quenching and enhancement with the SSP and LSP respectively, was 
decided to be used. 
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(c) Dual-spacer 
(c-i) Design of the dual-spacer 
In the original design of the dual spacer (Fig 31) , one of the two -COOH groups 
of Cypate is conjugated to a short spacer and the other, to a long spacer (DSP-Cy) . 
Ideally , Cypate is to be connected to GNP by both spacers as shown in Fig. 31. However , 
the design may easily produce several undesired products as shown in Fig. 32, especially 
because there is a difference in length of the two spacers. Sometimes only one spacer 
may be attached to a GNP and the other spacer is free. Some times two spacers are 
attached to two different GNPs and multiple GNPs are connected by the spacers (cross-
linking) . Slight cross-linking may be tolerable, because fluorescence will be quenched as 
long as Cypate is conjugated to GNP via the short spacer, and at least it does not emit 
non-specific fluorescence. Severe cross-linking may result in the GNP aggregation. 
, 
,./ 
-- (0 J 
"'-/ /" .-
/ \ Long /, 
" 
spacer Short spacer 
sPEG i 
Cypate 
Figure 31. Original design for the synthesis of GNP-DSP-mCy (ideal case) 
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(a) (b) 
Figure 32. Potential undesired product (a) incomplete conjugation (b) 
cross linking from the original design for the synthesis of GNP-DSP-mCy 
In addition, the synthesis of DSP-Cy has been difficult. The Nantz group has 
attempted to synthesize the DSP-Cy via the approaches of (1) solid-phase amide 
coupling, (2) solid-phase oximation coupling, and (3) solution-phase oximation coupling 
(from their report to DOD). None of them were successful due to the damage in Cypate 
molecule during the purification process. 
We, therefore, took a new approach to resolve these issues: A ring-shaped dual 
spacer (rDSP) was designed (Fig. 33). The design was commissioned to a company to 
produce it (NeoGroup Inc., Cambridge, MA). In the rDSP, the two ends of long spacer 
are attached to the two ends of the short spacer, making a circular shape. The rDSP has 
one single -SH group for reacting to GNP surface, and a single -ONH2 group for reacting 
with m-Cypate. This rDSP can be used to connect m-Cypate to GNP in the same manner 
that the nSSP or LSP does. 
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Fi gure 33. The chemical structure of the ring-shaped dual spacer (rDSP) 
To facilitate the synthesis of the rDSP, the structures of the short and long spacers 
were slightly modified. Our short spacer was HS-(CH2)2-NHC(O)-GGRGGG-
C(O)(CH2)-ONH2. Here, the following modifications were performed: at the -SH end, 
HS-(CH2)2-NH- was replaced by HS-CH2-CH(NH2)-C(O)- which provides a side group 
for connecting the new long spacer section later. At the -ONH2 end for Cypate reaction, -
CH2-ONH2 was replaced by -NH-CH(COOH)-CH2-NH-C(O)-CH2-0-NH2' which has a 
side group -COOH for connecting the long spacer later. However, it introduces extra 
length [-CH(COOH)-CH2-NH-C(O)-]. To keep the length of the short spacer to be short 
for quenching while maintaining the peptide substrate function, we removed one Glycine 
in the peptide sequence, having -GRGGG- instead of -GGRGGG-. 
CH2-CH(COOH)-NH2 provides the ,SH group, which gives and extra length of -CH2-
CH2(COOH)-NH-. For the -ONH2 end, using H2N-CH(COOH)-CH2-NH-C(O)-CH2-0-
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NH2 results in extra length of C(O)-CH2-CH2-NH-C(O)-CH2. Hydrocarbon chain and 
PEG are connected through amide-bond, which also introduce extra length [-NH-C(O)-]. 
To compromise these length increases and maintain the total length similar to our long 
spacer, the -CH2- number was reduced from 12 to 6, and EG number was reduced from 6 
to 5. 
(c-ii) Characterization and performance of the rDSP 
The absorption spectra of GNP, m-Cypate and GNP-rDSP-mCy are shown in 
Figure 34. The GNP-rDSP-mCy showed both GNP and mCy absorption peaks, 
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Figure 34. Absorption spectra of 8.0 nm GNP, GNP coated sPEG, GNP-
rDSP-mCy, and mCy 
Figure 35 shows the relative fluorescence of GNP-rDSP-mCy (GNP size, 8.0 nm) 




1 .......................................................................... . 
0.5 
or O+-_..I::=:::::t::=:::J..._--..,..._-L __ ..L--I 
Without uPA With uPA 
Figure 35. Fluorescence of GNP-rDSP-Cy (8.0 run GNP) at 100 nM 
Cypate, 0.9 nM GNP, before and after adding uPA at 1030 units/ml 
(Ex/Em 780/830 run) 
The fluorescence of GNP-rDSP-mCy was quenched by 93%, very close to the 
one with GNP-SSP-Cy (94%). When uPA was added, the fluorescence increased to 1.8 
times of the m-Cypate, which is slightly lower than the enhancement for the 8.0 run GNP 
with the LSP (2 times). 
In summary, with 8.0 run GNP, the rDSP provided the fluorescence quenching of 
93%, and the fluorescence enhancement of 1.8 times, upon uP A addition. This result 
confirms the functionality of the design of the novel contrast agent utilizing both 
fluorescence quenching and enhancement by GNPs. 
4. Cell Study 
(a) Short spacer performance 
The GNP-SSP-Cys showing satisfactory performance of the fluorescence 
quenching, and the restoration with uP A addtion (in PBS buffer) were tested for the 
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selected breast cancer cell lines. Two cell lines tested were: MCF-7 cells known to 
secrete little uPA (uP A-) as a control, and MDA-MB-231 cells expressing high level of 
uPA (uPA+). uPA+ cells produce and release uPA from the cells to the surrounding 
media. Therefore, the uP A concentration in the media increases with time. Here the cells 
were cultured in serum-free media and incubated for a predetermined time to let the uPA 
accumulate in the media. 
(a-i) uP A secretion of the cell lines 
To see the feasibility of our contrast agent in cell culture systems, before testing 
the GNP-SSP-Cy, the uP A concentration and its activity of the cell lines in the media 
needed to be confirmed. The cell study was done in the Bates group at University of 
Louisville, with the help of the group members (Dr. Tariq Malik and Ms. Levona Coxon). 
The uPA concentrations in the media were measured 8 and 32 hrs (arbitrarily chosen) 
after the cells were plated. The uPA quantification was done by enzyme-linked 
immunosorbent assay (ELISA). At 8 hrs, the uP A concentrations in both cell lines were 
at the lower limit of the ELISA, with a high noise level generated among the 4 duplicates 
of the sample (Fig. 36). At 32 hrs, MCF-7 cell line (uPA-) showed a low level (0.76±0.65 
ng/ml) of uP A. Nevertheless there was uPA in the medium. The MDA-MB-231 (uPA+) 
cell line showed the uP A concentration of 3 .15± 1.20 ng/m!. This concentration was 
approximately 1000 times lower than the concentration used in our experiments in PBS 
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Figure 36. uPA concentrations in the media containing MCF-7 (uPA-) or 
MDA-MB-231 (uPA+) cells, after 8 and 32 hrs of cell culturing 
(a-ii) Fluorescence change of GNP-SSP-Cy in cell lines 
The GNP-SSP-Cy with 8.0 nm GNP core was tested in MCF-7 (uPA-) and MDA-
MB-231 (uPA+) cell lines. This experiment was performed by Dr. Sharon Bloch in the 
Achilefu group at Washington University. The cells were plated and cultured for 32 hours 
to have a sufficient amount of uP A. GNP-sSP-Cy samples at 10 j.lM Cypate 
concentration were added to the media containing cells and incubated for 2 hrs assuming 
that longer reaction time will provide enough reaction time for lower uP A concentration. 
Since the cleaving of short spacer should takes place in the cell culture medium where the 
uPA is present, the fluorescence from the media was monitored (Fig. 36). For this study, 
a Pear Imager (Licor) was used to measure the fluorescence, with excitation 780 nm and 
the emission was detected from 805-830 nm. 
The fluorescence of GNP-SSP-Cy in the media without cells was measured as a 
control, and the fluorescence was at the noise level (5.2 RFU). In the media from the 
MCF-7 (uPA-) cell culture, the fluorescence became very high (183 RFU), indicating the 
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presence of uP A or some other biomolecules that cleaves the short spacer in the cell 






















Figure 37. Fluorescence of GNP-SSP-Cy in media without cells, with 
MDA-MB-231 cells, and with MCF-7 cells after 2 hr incubation. ExlEm: 
780/805-830 nm 
It is speculated that, a very long reaction time (2 hrs) allowed the low level of 
uPA in MCF-7 to react with the short spacer. In the media of MDA-MB-231 cells the 
fluorescence became 210 RFU, 15% higher than the one in the media of MCF-7 (uPA-) 
cells. For further studies, a study for the time dependent fluorescence restoration is 
suggested to be performed. 
(b) Fluorescence of GNP-LSP-mCy in cell lines 
The well performing GNP-LSP-mCy with the 8.0 nm GNP core showed the 
fluorescence level twice of that of the mCy alone (Fig. 27). The well performed GNP-
LSP-mCy was tested in cell lines of MCF-7 and MDA-MB-231 , by Dr. Sharon Bloch in 
the Achilefu group. It should be noted that this experiment should not be affected by uP A 
because there is no short spacer in this entity. The cell uptake of GNP-LSP-mCy in this 
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experiment is non-specific. The cell lines were treated with mCy and GNP-LSP-mCy at 
the same mCy concentration. Then the cells (not the media) were imaged by the NIR 
fluorescence microscope (Fig. 38) and the fluorescence was quantified by a photon 
counter built in the microscope, at Ex/Em 780/830 nm, 1, 3 and 24 hrs after the treatment 
(Fig. 39). 
For both cell lines, and at all incubation time, the fluorescence of cell treated with 
GNP-LSP-mCy was significantly higher (>= 10 times) than that with mCy, possibly due 
to both fluorescence enhancement and higher cell uptake rate of GNP-LSP-mCy than 
mCy due to the nano-size of the particle. The fluorescence ofmCy or GNP-LSP-mCy in 
two cell lines is at a similar level, because as previously described, this product does not 
have a specificity. 
MCF-7 MDA-MB-231 




Figure 38. Fluorescence of Cypate and GNP-LSP-mCy in (a) MCF-7 
(uPA-) and (b) MDA-MB-231 (uPA+) cells, 1, 3 and 24 hrs after the 
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Figure 39. Fluorescence of Cypate and GNP-LSP-mCy in (a) MCF-7 
(uPA-) and (b) MDA-MB-231 (uPA+) cells, 1, 3 and 24 hrs after the 
treatment (performed by Dr. Sharon Bloch) 
In general, these results suggest that GNP-LSP-mCy can provide high contrast in 
the cells, by enhancing the fluorescence of Cypate or by increasing the cell uptake rate or 




A. Theoretical Analysis on Fluorescence Alteration by GNP 
A thorough analysis on the fluorescence alteration by GNP was performed for the 
fluorophores frequently used in the biomedical research to understand how the system 
parameters (the GNP size, Ex/Ern wavelengths and intrinsic quantum yield of the 
fluorophore) and the distance between a fluorophore and a GNP affect the fluorescence 
output. 
To acqUlre fluorescence quenching effect, the fluorophores with the Ern 
wavelength near the GNP plasmon resonance peak are good candidates. For the 
fluorophores with Ern wavelengths sufficiently longer than the GNP resonance peak (e.g., 
far-red or NIR fluorophores), to achieve the same level of quenching, the distance 
between the GNP and the fluorophore needs to be very short (e.g., < 2 nrn). With bigger 
GNPs, for the same level of quenching, the distance between the fluorophore and the 
GNP needs to be shorter. 
The fluorescence enhancement is effective only if the Ern wavelength of the 
fluorophore is sufficiently longer than the GNP resonance wavelength. The fluorophore 
with lower quantum yield have a greater potential for fluorescence enhancement. The 
GNP size needs to be sufficiently large to enhance fluorescence effectively. Bigger GNPs 
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provide greater maximum fluorescence enhancement, and for bigger GNPs, the distance 
for the maximal enhancement is shorter than that for the smaller GNPs. 
The theoretical study results are highly beneficial for designing fluorescence 
manipulation by GNPs for the fluorophores. 
B. Development of NIR fluorescent contrast agent for specific cancer detection 
An NIR contrast agent for highly sensitive and specific breast cancer detection 
was developed, utilizing both the fluorescence quenching and enhancing ability of GNPs. 
The fluorophore was conjugated to a GNP via two molecular spacers. One was short for 
the fluorescence quenching and the other was long for the maximum enhancement. The 
short spacer contains a G-G-R motif, uPA (enzyme secreted by breast cancer) substrate. 
The NIR fluorophore Cypate was used because NIR can penetrate tissue deeper than the 
visible light and is a derivative of the FDA-approved ICG with functional groups for 
conjugation. The GNP is also conjugated with targeting molecule to guide the contrast 
agent to the cancer site. Normally this agent is not to emit fluorescence because of the 
short spacer. The short spacer is cleaved when the contrast agent is delivered to the 
cancer site by the targeting molecule where uPA is present and the distance between the 
Cypate and the GNP is controlled by the long spacer length, and thus the fluorescence is 
emitted at an enhanced level. 
The fluorescence quenching and restoration of Cypate conjugated to GNP via the 
short spacer was studied. For the Cypate conjugated 3.7 and 8.0 nm GNPs via the short 
spacer (2.5 nm, estimated by molecular simulation), the fluorescence was quenched by 96 
and 95%, respectively. When uPA was applied, the fluorescence was restored. A high 
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GNP concentration in the solution appeared to quench the fluorescence of the Cypate 
released from the GNP. For the GNP concentration of at 2.5 nM in the solution, 74% of 
the fluorescence was restored. 
Cypate fluorescence enhancement by GNPs at 3.7, 8.0, and 16.4 nm was studied 
using the spacers [HS-(CH2)mPEGn-ONH2] with a length range of 3.2-4.6 nm (m=12 or 
16, n=4, 6, or 8). GNPs at 3.7 nm appeared to be too small to enhance Cypate 
fluorescence. The spacer HS-(CH2)12PEG6-0NH2 (3.9 nm) provided the highest 
fluorescence among the GNP sizes tested. With the GNPs of size 8.0 and 16.4 nm, the 
fluorescence was enhanced up to 2.0 and 3.6 times, respectively, with the spacers tested. 
Experimental study results qualitatively agreed with the theoretical estimation, 
although the spacer lengths estimated by molecular simulation were 1~2 nm longer than 
the distance in the theoretical result. 
The performance of the novel dual spacer, containing both the short spacer section 
with the uPA substrate motif and the long spacer section for the maximal enhancement, 
was tested for the 8.0 nm GNP. The Cypate fluorescence was quenched by 93% when the 
dual spacer was conjugated with the GNP. With the uPA application, the fluorescence 
increased up to 1.8 times of the control. 
The sell study was performed with the contrast agent with the short or long 
spacers using two breast cancer cell lines, MCF-7 (uPA-) and MDA-MB-231 (uPA+). For 
the contrast agent with the short spacer (GNP-SSP-Cv). the Cypate conjugated to 8.0 nm 
GNP via short spacer was tested. The fluorescence of GNP-SSP-Cy was expected to 
increase from a quenched level only in the media with uPA+ cells. However, in the uPA 
quantification for both cell lines, it appeared the MCF -7. The results showed that in the 
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media without cells, the fluorescence of GNP-SSP-Cy was verly low (5 RFU). In the 
media with MCF -7 and MDA-MB-231 cells with the reaction time of 2 hours, the 
fluorescence increased to 183 and 210 RFU, respectively. The reason of the increase 
fluorescence in the MCF-7 cell medium might be due to small amount of uP A secretion 
by MCF -7 cells. For the contrast agent with long spacer, the Cypate conjugated to 8.0 
nm GNP via the long spacer providing the highest enhancement was applied to MCF-7 
and MDA-MB-231 cells. The fluorescence of the cells with GNP conjugated Cypate via 
the long spacer was 10 times higher than that of the cells with only Cypate. The higher 
fluorescence may be a result by both the fluorescence enhancement and by the high cell 
uptake rate caused by the GNP. 
In terms of the utility of the study results they provide the information on how 
GNPs alter the fluorescence of fluorophores, which can be beneficially utilized for the 
fluorescence alteration in biosensing and imaging. The optical contrast agent developed 
here has a high sensitivity by enhanced signal. The targeting molecules and the enzyme-
triggered fluorescence emission offer dual specificity and also characterize the cancer 
type, which can be used for cancer diagnosis as well as cancer detection. This unique 
construct provides the biomarker-specific emission as specific as FRET or molecular 
beacon, but with higher sensitivity, without the restriction for DNA/RNA segments only. 
The design of the contrast agent can also be used in biosensing/imaging with any 
enzyme-substrate combination. The surface of GNPs can also be treated with cancer 




A. Completion with Targeting Molecules 
The contrast agent in this study is designed to have targeting molecule for cancer-
specific delivery. A breast cancer drug Tamoxifen (Tam), and a monoclonal antibody 
Herceptin (Her) are currently being tested for targeting ER+ or HER2+ breast cancer, 
respectively. The targeting ability of the GNP-rSP-mCy with Tamoxifen (GNP-rSP-
mCy/Tam)or Herceptin (GNP-rSP-mCy/Her) are being studied. The performance of the 
final GNP products are suggested to be tested in various breast cancer cell lines. 
Tamoxifen and Herceptin have been used for breast cancer therapy. Therefore, 
therapeutic functions of the contrast agent are also suggested to be studied. 
B. Application of the Concept for Other Target Enzyme 
The contrast agent developed in this study is a model system for breast cancer 
imaging. In future, the enzyme-triggered fluorescence mechanism can be applied for 
other enzyme detection by replacing the uPA substrate motif in the short spacer to the 
respective substrate of the target enzyme in biosensing or bioimaging. 
For biosensing which has less requirement on tissue penetration of the 
fluorescence or the safety of the fluorophore, many other fluorophores or quantum dots 
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may be used. It is suggested that simultaneous multi-enzyme detection system be 
developed by using a mixture of contrast agents, in which each contrast agent is for the 
detection of a particular enzyme, with a fluorophore emitting fluorescence at a different 
wavelength from others. 
c. Development of multi-functional nano-contrast agent 
Our research group has been studying iron oxide nanopartic1e-induced 
hyperthermia using alternating electromagnetic (AEM) field for cancer treatment for 
years. In the future, the contrast agent developed in this study can incorporate iron oxide 
nanopartic1e as a core with a gold shell to provide both optical detection and non-invasive 
hyperthermia within one-entity. Iron oxide nanopartic1e can also be used as MRI contrast 
agent. Gold nanoshell can be used for X-ray/CT imaging contrast agent due to increased 
scattering. The gold surface can be treated with targeting molecule and cancer drugs. 
Therefore, this multi-functional design may provide non-invasive, targeted cancer 
delivery and multi-modality imaging contrast for sensitive and specific cancer detection, 
and multi-treatment (drug and hyperthermia) within one entity. 
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APPENDIX I 
GOLD NANOPARTICLES FOR 
SENSITIVITY ENHANCEMENT IN REAL-TIME, IMMUNO-
OPTICAL CARDIAC MARKER SENSING 
A. BACKGROUND 
1. Four Cardiac-marker Sensing System for AMI Diagnosis 
Acute myocardial infarction (AMI) is the world's leading cause of morbidity and 
mortality. It is also a disease with a high rate of misdiagnosis due to the low sensitivity 
of the current diagnostic tools used in the emergency room [Wu, et al., 1999; Pope, et al., 
2000]. A better method for AMI diagnosis is to quantify the elevation of cardiac markers 
in blood plasma [Bernard, et al., 1979]. Currently, the cardiac markers are usually 
quantified in a central laboratory, and it often takes hours from when it is ordered till the 
results are received. Due to the needs for urgent treatment of the disease nature, a rapid 
and accurate point-of-care (POC) system is critical. The fiber-optic, fluorophore-
mediated, immuno-sensing system has demonstrated accurate, sensitive, rapid, and 
reliable simultaneous quantification of various biomarkers [Wu, et al., 1999; Pope, et al., 
2000]. The Kang group has been developing portable, near-infrared, real-time multi 
cardiac marker sensing system by immuno-optical sinsing. The four markers selected for 
our sensing system were as follows: B-type natriuretic peptide (BNP) and C-reactive 
protein (CRP) are crucial markers for the diagnosis of congestive heart failure and acute 
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coronary syndromes [Maisel, et al., 2002; Sabatine, et al., 2002]; Myoglobin (MG) and 
cardiac troponin I (cTnl) are important markers for early diagnosis of a heart attack 
[Apple, et al., 1999]. Our research group has previously determined the clinically 
important sensing range of the marker to be 26~260 pM for BNP; 30~300 pM for cTnl; 
4~40 nM for MG and 5.6~56 nM for CRP [Tang, et al., 2005; Tang and Kang, 2006; 
Tang et al., 2006], bOased on the assessment of the clinical results. For BNP and cTnI, 
their concentrations in plasma at an early disease stage are only tens of pico molar level, 
requiring extremely high sensitivity, which can be improved by enhancing the signal. 
2. GNP Reagent for Fluorescence Enhancement 
The Kang group has been studying to use GNPs in the fluorophore mediated, 
fiber-optic biosensing to enhance the fluorescence to improve the sensitivity of the sensor 
[Hong and Kang, 2006; Kang and Hong, 2006]. The sensor performs a fluorophore-
mediated sandwich immunoassay on the sensor surface, and the fluorescence intensity is 
correlated with the analyte concentration in blood plasma [Kang et al., 1997; Spiker et 
al., 1998; Kwon et aI., 2002; Baler et al., 2002]. 
In an attempt to enhance the sensitivity of the sensing system GNPs were applied 
to the sensor surface after the sandwich formation, and the fluorescence intensity was 
observed and compared with that without GNP application. The minimum distance 
between the GNP and the fluorophore was adjusted by a self-assembled monolayer 
(SAM) on the GNP surface. The effect of GNP size and SAM thickness was studied. 
Among the GNP-SAMs tested (GNP size of 2, 5, and 10 nm and SAM thickness of 1, 2 
and 3 nm), 5 nm GNPs coated with 2 nm SAMs (5 nm GNP-SAM2 nm) were found to 
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be the best enhancer, and the enhancement level was up to 230%. 
Hong and Kang [2006] also found that some solvents could also enhance the 
fluorescence of a fluorophore without denaturing the antibody on the sensor surface, by 
shifting the fluorophore excitation/emission wavelengths, and/or by changing the trans-
cis isomerization direction, and/or by shrinking fluorophores tagged proteins, so that the 
fiber received more fluorescence. They have tested various solvents and found that 1-
butanol and ethanol showed the highest and 2nd highest enhancement, respectively. 
To maximize the enhancement effect, Hong and Kang [2006] mixed the two 
enhancers, the GNP-SAM and the solvent, to form GNP reagent (GNPR). They have 
tested the GNPR of 5 nmGNP-SAM2nm in ethanol with Alexa fluorophore (Alex-647) 
for four-cardiac marker sensing and achieved sensitivity improvement by 1.5~3 times. 
In this study, our effort was focused on further improving the sensitivity by using 
GNPR with butanol. Improving sensitivity allows reducing of the sensor SIze and, 
therefore, the sample and reagents volume (i.e., assay cost reduction), and also 
portability. 
B. MATERIALS, INSTRUMENTS AND METHODS 
1. Sensor Preparation 
For the cardiac markers and their respective monoclonal antibodies, BNP was 
purchased from Bachem (Torrance, CA) and monoclonal IgG against human BNP was 
from Strategic Biosolutions (Newark, DE). cTnI, MG, and CRP, and their antibodies 
were obtained from Fitzgerald Industries (Concord, MA). 
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Four cardiac marker biosensors were constructed, following the protocol 
established by Tang et al. [2006]. Briefly the surface of four quarts fibers (Research 
International, Inc.; Monroe, WA) were treated and immobilized with streptavidin 
(Sigma!Aldrich, St. Louis, MO). 0.1 M ethanolamine (Sigma!Aldrich) was applied to 
terminate the reactive function groups on the sensor surface. The monoclonal antibodies 
(1 °Mab) against the respective markers were conjugated with biotin (Sigma! Aldrich) and 
immobilized on the surface of fiber via streptavidin-biotin bond, and the sensors were 
encased in a micro-sensing chamber. The fluorophore Alexa Fluor® 647 (AF647; max. 
excitation/emission wavelengths, 649/666 nm) was from Invitrogen (Carlsbad, CA). The 
respective second monoclonal antibodies (2°Mab) were conjugated with AF647 
following the manufacture's instruction. 
2. Assay Protocol with the Sensor 
The emulated plasma was prepared 103 mg/ml human serum albumin (HSA; 
Sigma! Aldrich) in the PBS buffered solution, because it provides similar physical 
properties for sensing [Hong and Kang, 2006]. Samples with cardiac markers were 
prepared by adding known amount of cardiac markers to the emulated plasma. 
The cardiac marker assay was proceeded as follows: a sample was introduced into 
the sensing chamber and incubated for 3 min with the sample circulating at a rate of 1.2 
cm/sec. The sensor was then washed with phosphate buffered saline with 0.1 % Tween 
20 (PBST, pH 7.4) for 1 minute in circulation to remove the unbound molecules in the 
sample. Then the baseline fluorescence was measured using the fluorometer (Analyte 
2000TM; Research International). The instrument has four sensing ports. AF647 tagged 
2°Mab, at a concentration of 10 /lg/ml, was then applied to the chamber and incubated for 
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4 minutes the reagent in the circulation mode to react with the bound analyte. For the 
simultaneous four marker sensing, all four 2°Mabs were mixed and applied to the sensing 
system. The sensor was washed with PBST for 1 minute and the second fluorescence 
readings were taken. The signal difference between this signal and the baseline 
subtracted by the negative control is the signal intensity of the sample. 
For preparation of the GNPR, 5nm-GNPs coated with citric acid were purchased 
from Ted Pella (Redding, CA). I-butanol was purchased from Sigma/Aldrich. For the 
sensing with a GNPR. When GNPR was used in sensing, there were slight changes in the 
sensing protocol: For the baseline measurement, the GNPR was applied before the 
sample incubation. For the signal by the sample, GNPRs were applied after the second 
antibody was reacted with the analyte on the sensor surface. The difference between the 
latter and the former was taken as the signal with GNPR. The enhancement was defined 
as the fluorescence signal with the GNPR divided by the fluorescence from the sensor 
without GNPR. 
3. Microfluidic System and Automated Sensing Operation 
The sensing chip and micro channel network of the sensmg unit were 
microfabricated by the Chong H. Ahn group [Sohn, et al.,2005 and Hong, et aI., 2008]. 
The system includes a polycarbonate mother board with imbedded network of the 
microchannels; a four-channel, plastic sensing module; a micro-solenoid pump (12 v, 50 
).lL per stroke, 2 W); seven micro-solenoid valves (12 v, 280 mW, Lee Co.; Westbrook, 
CT); a data acquisition (DAQ) card (USB-6008, 8 inputs, 12 bits, 10000 samples/s, 
multifunctional 110, National Instruments; Austin, TX); and a drive circuit with a power 
plug, a power switch, and a power LED. 
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C. RESULTS AND DISCUSSION 
1. Reduction in Sensor Size 
Here, we have attempted to reduce the sensor size from 3 to 1.5 cm by using 5 
nmGNP-SAM2 nm in butanol. Since BNP has the lowest sensing range among the four 
cardiac markers, BNP sensor size was our main concern. 
Figure API-1 shows the performance of the BNP sensors with the sensor size of 
(a) 3 and (b) 1.5 cm, with and without GNPR, when the total sensing time was 15 min. 
In terms of the signal intensity enhancement by GNPR, the signals were enhanced by 4 
and 3 times for the 3 cm and 1.5 cm sensors, respectively. For the 1.5 cm, the signal 
without GNPR was very low in the entire sensing range. The signal for the 1.5 cm sensor 
with GNPR was approximately 40% of that of the 3 cm sensor. Nonetheless, the 
correlation coefficient was 0.96 (0.95 for 3 cm sensor), and the signal to noise ratio (SIN) 
was 4.1 (3.8 for 3 cm sensor), showing that the performance of the 1.5 cm sensor was still 
satisfactory, but with less sample and reagent. 
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Figure API-I. Performance ofBNP sensor at sensor sizes of (a) 3 cm and 
(b) 1.5 cm with and without GNPR (5 nmGNP-SAM2 nm in butanol). 
The total sensing time, 15 min 
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3. Four Cardiac Marker Sensing by the Mini-sensor 
Since the sensing performance of the 1.5 cm BNP sensor was satisfactory, the 1.5 
cm sensor size was then tested for all four cardiac markers in the four sensor micro 
sensing chip. The size of the sensing chip for four cardiac marker was reduced from 4 x 4 
cm (for 3 cm sensors) to 2 x 2.5 cm (for 1.5 cm sensors) accordingly. A schematic 
diagram of the chip is shown in Fig. API-2. As previously shown by Hong, et aI. , [2008] , 
on the inner surface of the microchannel, bumps/baffles were microfabricated to create 
local turbulence, to facilitate the analyte transport to the sensor surface. The mini-
sensing chip requires a sample size of only 200 JlI , and therefore, only 0.5 ml of a blood 
sample is needed for an assay. 
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Figure API-2. (a) Schematic diagram of mini-sensing chip and (b) 
Enlarged diagram of a sensing chamber 
Figure API-3 shows the performance of the four-cardiac marker sensors with and 
without GNPR, when the entire senisng time was 15 min. For BNP and cTnI, the signal 
range without using GNPR was only 3~30 pA. With GNPR, the signal was enhanced by 
3 and 4 times, respectively. The SIN ratios were 4.1 and 4.5, and the correlation 
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coefficients were 0.96 and 0.97, respectively. For MG and CRP, the signal ranges 
without and with enhancer were 4- 105 pA and 90- 400 pA, respectively. The signals 
were enhanced by 5 and 2 times and the SIN ratios were 5.2 and 6.7 for MG and CRP, 
respectively. As can be seen from these values, these two markers do not need enhancer. 
But, since the four marker sensing needs to be done simultaneously with a single sample 
and reagents, GNPR was applied for all four sensors. 
All four 1.5 cm sensors showed linear relationships between the marker 
concentration and the signal intensity, with correlation coefficients above 0.95 . 
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D. CONCLUSIONS AND FUTURISTIC, PORTABLE ALL-IN-ONE DEVICE 
Our MEMS based sensing device with mini-sensing chips (2 x 2.5 cm) and novel 
gold nanoparticle reagent can accurately quantify four cardiac markers simultaneously at 
clinically significant concentration ranges within 15 min, requiring a plasma sample 
volume of only 200!il. The entire sensing system may be converted to be a highly 
portable, all-in-one, point-of-care (POC) sensing device. For the next step, the system 
may be further optimized considering both sensitivity, time, and cost, by comparing the 
performance of GNPR with ethanol and butanol in the mini-sensing system. 
In the future, the current sensing system of the fluorometer, micro fluidic flow 
control unit, display monitor and input keyboard may be put into a highly portable, all-in-
one device at a size of 30 x 20 x 15 cm (Fig. API-4). With disposable sensing chip and 
sample reagent containers, a four cardiac marker sensing may be performed withing 15 
min in an emergency room or even in an emergency-medical-service vehicle. 
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APPENDIX II 
HOLLOW GOLD NANOSPHERE FOR 
CONDITIONAL FLUORESCENCE QUENCHING 
A. BACKGROUND 
Solid, spherical gold nanoparticles (GNPs) are known to generate surface 
plasmon field resonance around 520 nm [Eustics and EI-Sayed, 2006]. Other gold 
nanostructures such as shells, thin films, nanorods, and triangles also generate strong 
surface plasmon field by the visible light, and the wavelength of their absorption peaks 
are strongly dependent on the dimension of their nanostructure [Hu, et al., 2006]. Dr. Jin 
Z. Zhang's group at the University of California, Santa Cruz, California, developed 
hollow gold nanospheres (HGNs) with various plasmon resonance peaks in the entire 
range of the visible and NIR wavelengths, by varying the diameter-to-wall thickness ratio 
[Hu, et al., 2006; Schwartzberg, et al., 2006]. 
HGNs tuned for NIR feature several advantages. Their strong absorption in NIR 
makes the HGN an effective absorption contrast agent for NIR imaging. For example, the 
extinction coefficient of hemoglobin, one of the strongest bio-chromophore in NIR, is in 
the range of 3 x 102 /cm M [Kim, et aI., 2005]. From our measurement and calculation, 
the extinction coefficient of the HGNs that we currently use is in the range of 5-12 x 
lOlD/cm M, which is approximately 8 orders of magnitude higher than that of 
hemoglobin. Because of this high absorption in NIR they were used for NIR 
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hyperthermia very effectively [Ji, et ai., 2007; Lu, et ai., 2009]. GNPs are also strong 
scatterers for X-ray and therefore HGNs can be effective X-ray/CT contrast agents 
[Zhang, 2010]. These multiple properties allow HGNs be excellent candidates for both 
cancer detection (NIR fluorescence/X-ray/optical imaging) and treatment. 
According to our theoretical analysis on fluorescence quenching by GNP [Chapter 
IV, section 1], when the Ex/Em wavelengths of a fluorophore are near the plasmon 
resonance wavelength of the particle, the fluorescence is strongly quenched. Therefore, 
HGNs with plasmon resonance peak in the far red or NIR region can be a highly effective 
quencher for NIR fluorophores. 
Here, the conditional emission of Cypate fluorescence was studied utilizing 
HGNs, using the short spacer containing the -G-G-R- motif to be cleaved by uPA 
[Chapter IV, section 2]. HGNs studied were: (i) HGN654 : The particle has the outer 
diameter of 41 run with the hollow center diameter of 28 nm (28/41 run). Its plasmon 
resonance peak is at 654 run; (ii) HGN786 : The hollow and outer diameter are 43 and 53 
nm, respectively, and the plasmon resonance peak is at 786 run. 
B. MATERIALS, INSTRUMENTS AND METHODS 
HGN654 (3.32x10-6 !J,M) and HGN786 (2.49x10-6 !J,M) stabilized with citric acid in 
water were provided by the Zhang group at the University of California, Santa Cruz. 
Cypate and Cypate conjugated short-spacer HSCH2CH2NH-G-G-R-G-G-G-NH2 (sSP-
Cy), sPEG and uPA were as described in the materials section (Chapter III). 
HGN-sSP-Cy was synthesized and purified using the same methods used for 
synthesizing GNP-sSP-Cy (Chapter III). For HGN654, the concentration of HGN654 and 
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Cypate in the HGN654-SSP-Cy was quantified by the absorption at 654 and 780 run, 
respectively. For HGN786-sSP-Cy because the absorption of HGN786 and Cypate 
significantly overlap, we were not able to quantity these by the spectroscopic method. 
The fluorescence of the sample in O.OOIM PBS buffer was measured in a 96-well 
Uniplate using a Spectra Gemini XPS fluorometer at the excitation and emission 
wavelengths of 780 and 830 run, respectively. 
C. RESULTS AND DISCUSSION 
1. Fluorescence Quenching and Restoration of HGN654-SSP-Cy 
The fluorescence of HGN654-SSP-Cy was measured and compared to that of the 
free sSP-Cy at the same sSP-Cy concentration (5 !J.M); (Fig. 1). At this Cypate 
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Figure APII-l. Absolute and relative fluorescence of HGN654-SSP-Cy, 
before and after adding uP A (30 min after uP A addition). [Experiment 
conditions: Cypate conc., 5 !J.M; HGN cone., 3.5xl0-3 nM; Ex/Em 780/830 
run] 
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In HGN654-SSP-Cy the Cy fluorescence was quenched by 84%. Compared to sSP-
Cy with 3.7 or 8 nm GNPs (with GNP concentration 31 or 7 nM, quenched by 96 or 95%, 
respectively) this was slightly less. 
After uPA was added (1030 unit/mL, at a sufficient amount) to the HGN654-SSP-
Cy sample, the fluorescence was restored to 80% of the free Cypate. 
2. Fluorescence Quenching and Restoration of HGN786-SSP-Cy 
The absorption peak (786 nm) of HGN786 is very close to the emISSIOn 
wavelength of Cypate (830 nm). HGN786 and Cypate in the final product (HGN786-SP-
Cy) could not be determined because the HGN absorption peak highly overlaps with that 
of Cypate. Therefore, only the absolute fluorescence before and after adding uP A were 
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Figure APII-2. Fluorescence of HGN786-SSP-Cy before and after adding 
uP A (30 min after uPA addition), with Ex/Em 780/830 nm. 
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The fluorescence ofHGN786-SP-Cy without uPA was 0.52 RFU, at the lower limit 
of the instrument, suggesting that the Cypate fluorescence was almost or completely 
quenched by HGN786• When uPA was added to the sample, the fluorescence increased to 
5.0 RFU. Assuming that both HGN654 and HGN786 have similar restoration rate, the 
fluorescence of HGN786-SP-Cy is 53% lower than that of HGN654-SP-Cy, and HGN786 
appears to quench more effectively than HGN654 does, due to its stronger absorption at 
the Cypate emission peak's wavelength. 
D. CONCLUSIONS 
The two HGNs, which absorption wavelengths are adjusted in NIR, especially 
HGN786, demonstrated an excellent ability for quenching Cypate fluorescence when 
Cypate is conjugated on them via the short spacer. The conditional fluorescence emission 
in the presence of the cancer-secreting enzyme was well confirmed. This conditional 
emission property is especially important because it adds an imaging-contrast ability to 
the nano-entity that already possesses multi-functions of NIR absorption contrast; X-ray 
scattering contrast; and photo-thermal property. 
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